

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2006236365 B2**

(54) Title
C. perfringens alpha toxoid vaccine

(51) International Patent Classification(s)
A61K 39/08 (2006.01) **A61P 31/04** (2006.01)

(21) Application No: **2006236365** (22) Date of Filing: **2006.04.17**

(87) WIPO No: **WO06/113772**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/672,289	2005.04.18	US

(43) Publication Date: **2006.10.26**

(44) Accepted Journal Date: **2012.02.02**

(71) Applicant(s)
Schering-Plough Pty. Limited

(72) Inventor(s)
Jayappa, Huchappa;O'Connell, Kevin

(74) Agent / Attorney
Griffith Hack, Level 29, Northpoint 100 Miller Street, North Sydney, NSW, 2060

(56) Related Art
Lovland, A et al., Avian Pathology, 2004, Vol.33, No.1, pages 83-92
Schoepe, H et al., Infection and Immunity, 2001, Vol. 69, No.11, pages 7194-7196
WO 1993/023543 A1
Stevens, DL et al., JID, 2004, Vol.190, pages 767-773

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 October 2006 (26.10.2006)

PCT

(10) International Publication Number
WO 2006/113772 A1

(51) International Patent Classification:

A61K 39/08 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:

PCT/US2006/014669

(22) International Filing Date: 17 April 2006 (17.04.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/672,289 18 April 2005 (18.04.2005) US

(71) Applicant (for all designated States except US): **SCHERING-PLOUGH LTD.** [CH/CH]; Weyrstrasse 20, P.O. Box, Ch-6000 Lucerne 6 (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JAYAPPA, Huchappa** [US/US]; 6323 South 104th Street, Omaha, Nebraska 68127 (US). **O'CONNELL, Kevin** [US/US]; 6207 South 159th Street, Omaha, Nebraska 68135 (US).

(74) Agent: **DAVIS, Michael, D.**; Schering Corporation, 2000 Galloping Hill Road, Patent Department K-1-6 1990, Kenilworth, New Jersey 07033 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: C. PERFRINGENS ALPHA TOXOID VACCINE

(57) Abstract: The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes methods of making these vaccines.

WO 2006/113772 A1

5

C. PERFRINGENS ALPHA TOXOID VACCINE

10

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a non-provisional application that claims priority under 35 U.S.C. § 119(e) of provisional application U.S. Serial No. 60/672,289 filed April 18, 2005, the contents of which are hereby incorporated by reference in their entireties.

15

FIELD OF THE INVENTION

20

The present invention relates to vaccines comprising *C. perfringens* Type *alpha* toxoids, antigenic fragments thereof, inactivated antigenic fragments of *alpha* toxins, and any combinations thereof. The present invention further relates to methods of using with these vaccines to protect animals against clostridial diseases. The present invention also relates to methods of making these vaccines.

25

BACKGROUND

30

Clostridium perfringens (*C. perfringens*) is an anaerobic bacterium that is naturally found in soil, decaying organic matter, and as part of the normal gut flora of animals, including humans. *C. perfringens* is also the etiological agent for numerous clostridial diseases found in economically valuable domestic animals. *C. perfringens* produces a number of toxins that cause pathogenic effects in animals, including the *alpha* toxin, the *beta* toxin, the *beta* 2 toxin, the *epsilon* toxin, the *theta* toxin, the *mu* toxin, the *delta* toxin, the *iota* toxin, the *kappa* toxin, and the *lambda* toxin. Moreover, *C. perfringens* encodes other biologically active substances that can cause pathological effects, including: hyaluronidase, acid phosphatase, protease, collagenase, sulfatase and neuraminidase.

35

Different strains of *C. perfringens* are designated as biotypes A through E, depending on the spectrum of toxins that the particular bacterium produces [Justin *et al.*, *Biochemistry* 41:6253-6262 (2002); McDonel,

5 *PHARMACOLOGY OF BACTERIAL TOXINS*; F Dorner and J Drews (eds.)
Pergamon Press, Oxford (1986)]. Initially, such typing was based on
serologic neutralization assays in mice or guinea pigs. More recently,
molecular typing methods employ polymerase chain reaction (PCR)
targeted to genetic sequences that encode one of the numerous toxins of
10 *C. perfringens*.

Intestinal clostridiosis in horses has been correlated with high
concentrations of *C. perfringens* Type A in the gut. Afflicted equine have a
profuse watery diarrhea and a high mortality rate. *C. perfringens* Type A
15 also has been linked to enteric disease in suckling and feeder pigs, with
the symptoms including mild necrotizing enteritis and villous atrophy
[Songer, *Clin. Micro. Rev.*, 9(2):216-234 (1996)].

Clostridial diseases caused by *C. perfringens* are characterized by sudden
20 death in well-fleshed birds with confluent fibrinonecrotic lesions ("Turkish
towel") in the small intestine (enteric forms), and/or *C. perfringens*-
associated hepatitis with cholangiohepatitis, or fibrinoid necrosis in the
liver. Afflicted birds undergo a rapid course of depression, diarrhea, and
dehydration. Mortality ranges from 2% to 50%. Liver pathology leads to
25 carcass condemnations at slaughter.

Necrotic enteritis (NE) is an example of a clostridial enteric disease
caused by *C. perfringens* that leads to significant economic consequences
in poultry. The disease is especially common in floor-reared broiler
30 chickens from 2 to 10 weeks of age, though the disease also has been
reported in turkeys and caged laying hens. Necrotic enteritis generally
occurs in poultry either as a secondary disease, or in a situation in which
the normal intestinal microflora are altered so as to allow the abnormal
proliferation of pathogenic *C. perfringens*. The prevalence of subclinical
35 necrotic enteritis is unknown, since the lesions can only be observed
through post-mortem examination. However, reports of impaired feed

5 conversion and reduced body weights have been attributed to the subclinical disease [Lovland and Kadhusdal, *Avian Path.* 30:73-81 (2001)]. Predisposing factors that lead to necrotic enteritis in both natural outbreaks and experimental models include: (a) coccidiosis, (b) migration of parasitic larvae, (c) feeds high in fish meal or wheat, and (d)
10 immunosuppressive diseases. In addition, necrotic enteritis can be experimentally reproduced by: (i) providing animals feed contaminated by *C. perfringens*, (ii) administering animals vegetative cultures orally or into the crop, or (iii) intraduodenal administering of broth cultures of bacteria-free crude toxins to the animals.

15 *C. perfringens* Types A or C are the two biotypes that cause necrotic enteritis in poultry, with *alpha* toxin being the most common toxin detected [Wages and Opengart, *Necrotic Enteritis*. pp: 781-785, In: *Disease of Poultry*, 11th ed., (eds., Saif *et al.*), Iowa State Press, Ames, IA (2003)].
20 Indeed, greater than 90% of the *C. perfringens* isolates obtained from forty-two Type A infected fowl produced a lethal *alpha* toxin, along with sialidase, and the *theta* and *mu* toxins [Daube *et al.*, *AJVR* 54:496-501 (1996)]. In addition, enterotoxin produced by *C. perfringens* Type A has been identified in chickens with necrotic enteritis and may play a role in the
25 intestinal disease [Niilo, *Can. J. Comp. Med.* 42:357-363 (1978)].

Recently, it has been reported that *C. perfringens* Type A or Type C can encode the *cpb2* gene [Gilbert *et al.*, *Gene* 203:56-73 (1997)] and express its product, the *beta* 2 toxin. A strong correlation between the expression
30 of *beta* 2 toxin and neonatal enteritis in swine has been observed [Bueschel *et al.*, *Vet Micro* 94:121-129 (2003)]. The *beta* 2 toxin also has been implicated as a pathogenic factor in enteritis of horses and cattle. Bueschel *et al.*, *supra*, further reported that 37.2% of the three thousand and twenty *C. perfringens* isolates that they obtained encoded the *beta* 2
35 toxin, and of the *C. perfringens* Type A isolates examined, 35.1% encoded the *beta* 2 toxin. The limited sample (n=5) of avian *C. perfringens* Type A

5 field isolates were found to be $\approx 35\%$ positive for the *cpb2* genotype, and
40% of these also expressed the *beta 2* toxin. In addition, employing
PCR, Engstrom *et al.*, [*Vet Micro* 94:225-235 (2003)] found that 12% of the
C. perfringens isolates from chickens with hepatitis also were positive for
cpb2. The enterotoxin of *C. perfringens* Type A has also been shown to
10 be pathogenic in chickens, causing accumulation of fluid in a ligated
intestinal loop model [Niilo, *Appl. Micro.* 28:889-891 (1974)].

Current efforts to control *C. perfringens* rely upon sanitary measures and
placing antibiotics in the animal feed. The clostridial component of the
15 disease responds well to antibiotics and is generally suppressed by
antibiotic feed additives and ionophorous, anticoccidial drugs. However,
antibiotics are costly and subject to increasing concerns related to the
promotion of bacterial resistance.

20 Vaccination also has become an important control measure in domestic
animals, since the course of many *C. perfringens*-associated diseases is
rapid and often fatal. For example, U.S. Patent No. 4,292,307 defines one
"universal" multivalent vaccine prepared from toxoids of *C. perfringens*
Type A, Type B, and Type D that further includes toxoids from *Cl.*
25 *oedematiens*, and *Cl. septicum* toxoid. In addition, vaccines are
commercially available that are often multivalent and consist of inactivated
cells, toxins, or combinations of these two [see, Songer, *Clin. Micro. Rev.*,
9(2):216-234 (1996)].

30 Vaccination of female livestock may also elicit passive protection of their
subsequently born offspring. Passive protection of mammalian neonates
against pathologic *Clostridial* infections relies upon the transfer of specific
antibody in the form of colostral antibodies. For example, Smith and
Matsuoka [*Am. J. Vet. Res.* 20:91-93 (1959)] employed an inactivated
35 vaccine to inoculate pregnant sheep and reported maternally induced
protection of young lambs against the *epsilon* toxin of *C. perfringens*.

5 Passive immunity in young mammals typically lasts 2 to 3 weeks [Songer, *Clin. Micro. Rev*, 9(2):216-234 (1996)].

10 In contrast to suckling mammals, passive immunity in avians has several obvious shortcomings, most notably, the complete lack of the maternal antibodies obtained from milk. Though passive immunity is just one possible explanation for their observed correlation, Heier *et al.*, [Avian Diseases 45:724-732 (2001)] did report that the survival of chicks was significantly higher in Norwegian Broiler flocks having higher titers of specific, naturally occurring maternal antibodies against *C. perfringens*
15 *alpha* toxin than those flocks having low titers. In addition, Lovland *et al.* [Avian Pathology 33(1):83-92 (2004)] reported results that were consistent with modest passive protection of the progeny of hens that had been inoculated with vaccines based on *C. perfringens* Type A or Type C toxoids, as compared to the progeny of unvaccinated hens.

20 Heretofore, commercially significant protection from *C. perfringens* did not appear be attainable unless maternal antibodies for most, if not all of the pathologic components produced by *C. perfringens* bacteria were present in the inoculum. For example, vaccination of the dam with a product that
25 does not contain enterotoxin only offers partial protection to piglets, and anti-*epsilon* toxin antibody in mother goats protects against death from toxemia, but not against enterocolitis [Songer, *Clin. Micro. Rev*, 9(2):216-234 (1996)].

30 Indeed, despite the tabulation of an impressive quantity of data regarding the various biotypes of *C. perfringens* and their corresponding toxins and deleterious bioactive substances, clostridial diseases in food producing animals remain a significant economic problem for farmers. Therefore,
35 there is a need to provide additional means for protecting livestock against the pathological effects of *C. perfringens*. More particularly, there remains a need to provide a safe and effective vaccine against *C. perfringens* in

poultry. Moreover, there is a need to provide a simple vaccine against *C. perfringens* that can be administered to female animals, especially fertile and/or pregnant female livestock, that will passively protect their offspring.

The citation of any reference herein should not be construed as an admission that such reference is available as "prior art" to the instant application.

SUMMARY OF THE INVENTION

The present invention relates to vaccines against *C. perfringens* that comprise a *C. perfringens alpha* toxoid, and/or an antigenic fragment of a *C. perfringens alpha* toxoid, and/or an inactive antigenic fragment of a *C. perfringens alpha* toxin, and/or any combination thereof as an antigen.

The present invention further relates to vaccines that consist essentially of a single *C. perfringens* Type *alpha* toxoid, and/or an antigenic fragment of a *C. perfringens alpha* toxoid, and/or an inactive antigenic fragment of a *C. perfringens alpha* toxin, and/or any combination thereof as an antigen.

The present invention provides the following items (1) to (29):

(1) A vaccine against *C. perfringens* comprising a *C. perfringens alpha* toxoid supernatant that was concentrated by ultrafiltration and has 2 or more Total Combining Power (TCP);

wherein the *C. perfringens alpha* toxoid supernatant comprises an *alpha* toxoid antigen; with the proviso that only a single *C. perfringens* Type *alpha* toxoid antigen is present in said vaccine.

(2) The vaccine of item (1), wherein the antigen is in a cell-free preparation.

(3) The vaccine of item (1), wherein the vaccine is for administration to a chicken.

(4) The vaccine of item (1), wherein the antigen is a recombinant polypeptide.

- (5) The vaccine of item (3) wherein one to two doses of 0.25 - 0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of a chicken vaccinated with the vaccine.
- (6) The vaccine of item (1), wherein said antigen is selected from the group consisting of a *C. perfringens* Type A *alpha* toxoid and a *C. perfringens* Type C *alpha* toxoid.
- (7) The vaccine of item (1), further comprising an adjuvant.
- (8) The vaccine of item (1), wherein a water-in-oil emulsion comprises the antigen.
- (9) The vaccine of item (8), wherein the water-in-oil emulsion was prepared with a 70% oil phase and a 30% aqueous phase.
- (10) The vaccine of item (6), wherein the antigen is a *C. perfringens* Type A *alpha* toxoid.
- (11) The vaccine of item (1), which is a multivalent vaccine further comprising one or more of the following toxins: *C. perfringens beta* toxin, *C. perfringens beta* 2 toxin, *C. perfringens* enterotoxin, *C. perfringens epsilon* toxin, *C. perfringens iota* toxin, *C. perfringens kappa* toxin, *C. perfringens lambda* toxin, *C. perfringens theta* toxin, *C. sordellii* hemorrhagic toxin, *C. sordellii* lethal toxin, *C. difficile* A toxin, *C. difficile* B toxin, *C. septicum alpha* toxin, *C. novyi alpha* toxin, and *C. novyi beta* toxin.
- (12) The vaccine of item (11), wherein the multivalent vaccine further comprises one or more viral antigens, one or more bacterial antigens, and one or more parasitic antigens;
- wherein the one or more viral antigens is from one or more of the following sources: infectious bursal disease virus, infectious bronchitis virus, reovirus, and Newcastle disease virus;
- wherein the one or more bacterial antigens is from one or more of the following sources: *E. coli*, *Salmonella*, and *Campylobacter*; and
- wherein the one or more parasite antigens is from *Eimeria*.
- (13) The vaccine of item (1), which is a multivalent vaccine that further comprises one or more additional antigens;

wherein the additional antigen is from one or more of the following sources: infectious bursal disease virus, infectious bronchitis virus, reovirus, Newcastle disease virus, *E. coli*, *Salmonella*, *Campylobacter*, and *Eimeria*.

(14) A vaccine consisting essentially of an antigen selected from the group consisting of a single *C. perfringens* Type *alpha* toxoid, an antigenic fragment of the *alpha* toxoid, an inactive antigenic fragment of a single *C. perfringens* Type *alpha* toxin, and any combination thereof;

wherein the single *C. perfringens* Type *alpha* toxoid and the inactive antigenic fragment of the single *C. perfringens* Type *alpha* toxin are the same Type; and

wherein one to two doses of 0.25 - 0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of a chicken vaccinated with the vaccine.

(15) A method of providing passive immunity against multiple poultry diseases to the progeny of a female avian comprising administering the vaccine of item (12) to the female avian prior to her laying of the eggs that comprise the progeny; wherein the progeny are provided passive immunity from multiple diseases.

(16) A method of providing passive immunity against a clostridial disease to the progeny of a female avian, said method comprising administering the vaccine of item (1) to the female avian prior to her laying of the eggs that comprise the progeny; wherein the progeny are provided passive immunity.

(17) The method of item (16) wherein the avian is a chicken or a turkey.

(18) The method of item (16) wherein the clostridial disease is a clostridial enteric disease.

(19) The method of item (18) wherein the clostridial enteric disease is necrotic enteritis.

(20) The method of item (16) wherein the clostridial disease is selected from the group consisting of cholangiohepatitis, gangrenous dermatitis, and cellulitis.

(21) A method of making a *C. perfringens alpha* toxoid vaccine comprising:

- (a) growing a *C. perfringens* cell in a culture medium to produce a quantity of cultured cells; wherein said quantity of cultured cells secrete a *C. perfringens alpha* toxin into the cell medium;
- (b) inactivating the secreted *alpha* toxin to produce a *C. perfringens alpha* toxoid;
- (c) removing a majority of the quantity of cultured cells from the culture medium to form a *C. perfringens alpha* toxoid supernatant; and
- (d) adjusting the concentration of the *C. perfringens alpha* toxoid supernatant so that it is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of an avian that has been vaccinated with either one or two doses of 0.25 - 0.6 mL per dose of said vaccine.

(22) The method of item (21), further comprising mixing the *C. perfringens alpha* toxoid supernatant with a water-in-oil emulsion.

(23) The method of item (22), wherein the water-in-oil emulsion is prepared with 70% oil phase and 30% aqueous phase.

(24) The method of item (23) wherein the *C. perfringens* cell is a single *C. perfringens* Type cell.

(25) The method of item (24) wherein said single *C. perfringens* Type cell is selected from the group consisting of a *C. perfringens* Type A cell and a *C. perfringens* Type C cell.

(26) A vaccine against *C. perfringens* for a chicken comprising a *C. perfringens* Type A *alpha* toxoid supernatant that was concentrated by ultrafiltration and has 2 or more Total Combining Power (TCP);

wherein the *C. perfringens* Type A *alpha* toxoid supernatant comprises an *alpha* toxoid antigen;

wherein a water-in-oil emulsion comprises the antigen; and

wherein one to two doses of 0.25 - 0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of a chicken vaccinated with the vaccine; with

the proviso that only a single *C. perfringens* Type *alpha* toxoid antigen is present in said vaccine.

(27) The vaccine of item (26) wherein the water-in-oil emulsion was prepared with a 70% oil phase and a 30% aqueous phase.

(28) Use of the vaccine of item (12) in the manufacture of a medicament for providing passive immunity against multiple poultry diseases to the progeny of a female avian.

(29) Use of the vaccine of item (1) in the manufacture of a medicament for providing passive immunity against a clostridial disease to the progeny of a female avian.

Preferably, one to two doses of 0.25 - 0.6 mL per dose of a vaccine of the present invention is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of an animal (*e.g.*, a chicken) vaccinated with the vaccine. In one embodiment of this type, the determination of antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of an animal vaccinated with the vaccine is performed six to seven weeks following the immunization. In a particular embodiment, a single dose of the vaccine is sufficient to induce at least 4 antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of the vaccinated animal, whereas, in an alternative embodiment, two doses of the vaccine are necessary. In a one embodiment the antigen has 2 or more Total Combining Power units (TCP).

In one such embodiment the animal is an avian. In a particular embodiment, the avian is a chicken. In another embodiment, the avian is a turkey.

In one embodiment, the antigen originated from a *C. perfringens* Type A cell, e.g., a *C. perfringens* Type A *alpha* toxoid. In another embodiment the antigen originated from a *C. perfringens* Type C cell, e.g., an inactive antigenic fragment of a *C. perfringens* Type C *alpha* toxin. In yet another embodiment the antigen originated from *C. perfringens* Type B. In still another embodiment the antigen originated from *C. perfringens* Type D. In yet another embodiment, the antigen originated from *C. perfringens* Type E. In still another embodiment, the vaccine comprises an antigen originating from a *C. perfringens* sub-type. In one embodiment, the vaccine comprises an antigen that is a single *C. perfringens* Type antigen, with the proviso that only a single *C. perfringens* Type antigen is present in that vaccine. In one particular embodiment of this type, the *C. perfringens* is Type A. In a related embodiment, the *C. perfringens* is Type C. In one embodiment the antigen is an *alpha* toxoid. In a particular embodiment of this type, the *alpha* toxoid is comprised by a *C. perfringens alpha* toxoid supernatant. In a specific embodiment, the vaccine comprises an *alpha* toxoid supernatant of a single *C. perfringens* Type, Type A.

In one vaccine of the present invention, the antigen is an *alpha* toxoid of an *alpha* toxin naturally encoded by a *C. perfringens* cell. In another vaccine of the present invention, the antigen is a recombinant polypeptide, i.e., one that is encoded by a gene that had been genetically manipulated. In an embodiment of this type, the recombinant polypeptide is an *alpha* toxoid in which enzymatic regions of the corresponding *alpha* toxin had been genetically removed or altered, but, one or more antigenic epitopes had been retained.

In a particular embodiment the antigen is in a whole cell preparation. In another embodiment, the antigen is in a cell-free preparation. In yet

another embodiment, the antigen is an *alpha* toxoid in a *C. perfringens alpha* toxoid supernatant. In a particular embodiment of this type, the *C. perfringens alpha* toxoid supernatant also is a cell-free preparation.

In another aspect of the present invention, a vaccine may also contain multiple antigens which may result in the production of antibodies of a variety of specificities when administered to an animal subject. Not all of these antibodies need to be protective against a disease. In a particular embodiment of this type, such antigens are also from *C. perfringens*. Thus, a vaccine of the present invention may contain various other active or inactivated pathogenic factors, along with an *alpha* toxoid. Therefore, in accordance with the present invention, the *alpha* toxoid can be combined with other clostridial and non-clostridial cells, toxoids, and extracts, as well as inactive antigenic fragments of *alpha* toxin.

One such multivalent vaccine described herein comprises a *C. perfringens alpha* toxoid, and/or an antigenic fragment of a *C. perfringens alpha* toxoid, and/or an inactive antigenic fragment of a *C. perfringens alpha* toxin, and/or any combination thereof, and further comprises a viral antigen and/or a bacterial antigen and/or a parasite antigen. In a particular embodiment of this type the viral source of the antigen is infectious bursal disease virus. In another embodiment, the viral source of the antigen is infectious bronchitis virus. In yet another embodiment, the viral source of the antigen is reovirus. In still another embodiment, the viral source of the antigen is Newcastle disease virus. In yet another embodiment, the bacterial source of the antigen is *E. coli*. In still another embodiment, the bacterial source of the antigen is *Salmonella*. In yet another embodiment, the bacterial source of the antigen is *Campylobacter*. In still another embodiment the parasitic source of the antigen is from *Eimeria*. In a particular embodiment of this type, the antigen employed in the vaccine is a part of an *Eimeria* merozoite, an *Eimeria* oocyst, or a mixture thereof. In a related embodiment the natural host of the parasite is an avian. In a

particular embodiment of this type the parasite is *Eimeria* and the natural host of the parasite is a chicken.

A multivalent vaccine of the present invention can also comprise one or more of the following antigens: *C. perfringens* beta toxin, *C. perfringens* beta 2 toxin, *C. perfringens* enterotoxin, *C. perfringens* epsilon toxin, *C. perfringens* iota toxin, *C. perfringens* kappa toxin, *C. perfringens* lambda toxin, *C. perfringens* theta toxin, *C. sordellii* hemorrhagic toxin, *C. sordellii* lethal toxin, *C. difficile* A toxin, *C. difficile* B toxin, *C. septicum* alpha toxin, *C. novyi* alpha toxin, and *C. novyi* beta toxin.

In a particular multivalent vaccine described herein, the vaccine comprises a *C. perfringens* alpha toxoid, and/or an antigenic fragment of a *C. perfringens* alpha toxoid, and/or an inactive antigenic fragment of a *C. perfringens* alpha toxin, and/or any combination thereof, and further comprises one or more viral antigens from infectious bursal disease virus, and/or infectious bronchitis virus and/or reovirus, and/or Newcastle disease virus, and/or bacterial antigens from *E. coli*, and/or *Salmonella*, and/or *Campylobacter*, and/or a parasitic antigen from *Eimeria*.

In an alternative embodiment, a multivalent vaccine described herein consists essentially of a single *C. perfringens* Type alpha toxoid, and/or an antigenic fragment of a *C. perfringens* alpha toxoid, and/or an inactive antigenic fragment of a *C. perfringens* alpha toxin, and/or any combination thereof. In a related embodiment, the vaccine further contains a viral antigen and/or a bacterial antigen and/or a parasitic antigen, as provided herein.

A vaccine of the present invention can also comprise an adjuvant. One popular animal adjuvant is an aluminum hydroxide adjuvant. An

5 alternative adjuvant can be comprised in a water-in-oil emulsion along with the antigen. In a particular vaccine of this type, the water-in-oil emulsion is prepared with a 70% oil phase and a 30% aqueous phase. In another embodiment, the adjuvant is specifically not an aluminum hydroxide adjuvant. In one such embodiment, the vaccine including a non-aluminum
10 hydroxide adjuvant is administered to poultry. In a particular embodiment, a vaccine comprises a *C. perfringens alpha* toxoid, an adjuvant, and one or more protective antigens, either recombinant or natural, obtained from a virus, bacterium, and/or a bacterial extract.

15 In another aspect, the present invention provides methods of providing active immunity to an avian by immunizing an avian with a vaccine of the present invention. In a particular embodiment the vaccine dosage for such active immunity is about 0.05 to about 0.1 mL. In one embodiment the avian is a turkey. In another embodiment the avian is a chicken. In still
20 another embodiment the avian is a pheasant. The present invention also provides a method of administering a multivalent vaccine of the present invention to an avian to protect it against multiple diseases.

The present invention also provides methods of providing passive
25 immunity to the progeny of a female animal (e.g., a pregnant female) comprising administering a vaccine of the present invention to the female animal (e.g., mother) prior to the birth of her progeny. In one embodiment, the female is an avian and the vaccine is administered to the avian female prior to her laying of the eggs that comprise the progeny. In this manner
30 her progeny are provided passive immunity. In one such embodiment, the avian is a chicken. In another embodiment, the avian is a turkey. In still another embodiment, the avian is a pheasant.

In a particular embodiment, the method provides passive immunity against
35 a clostridial disease to the progeny of the vaccinated animal. In one such method the clostridial disease is a clostridial enteric disease. In a

5 particular method of this type, the clostridial enteric disease is necrotic enteritis. In another such method the clostridial disease is cholangiohepatitis. In still another embodiment the method provides passive immunity against a clostridial disease to the progeny of the vaccinated animal as well as provides protection against gangrenous
10 dermatitis, septicum, and/or hepatitis.

In one embodiment, the method of providing passive immunity to the progeny of a female animal comprises administering a multivalent vaccine to the female animal to protect her progeny against multiple diseases. In a
15 particular embodiment of this type, the female animal is in the poultry family and her progeny are protected from multiple poultry diseases.

In a particular embodiment the dosage for providing passive immunity to the progeny of a female animal is about 0.25 mL per dose of the vaccine.
20 In another embodiment the dosage is about 0.4 mL per dose of the vaccine. In still another embodiment the dosage is about 0.6 mL per dose of the vaccine. In an embodiment exemplified below, the dosage is about 0.5 mL per dose of the vaccine.

25 The present invention further provides a process for making a *C. perfringens alpha* toxoid vaccine of the present invention. One such method comprises growing a *C. perfringens* cell in a culture medium to produce a quantity of cultured cells that secrete a *C. perfringens alpha* toxin into the cell medium. The *C. perfringens alpha* toxoid is then
30 produced by inactivating the secreted *alpha* toxin. A majority of the cultured cells are removed from the culture medium to form a *C. perfringens alpha* toxoid supernatant. In a particular embodiment of the method, the concentration of the *C. perfringens alpha* toxoid supernatant is adjusted so that it is sufficient to induce at least four antitoxin units
35 (A.U.) of anti-*alpha* toxin antibody per mL of antisera of an animal (e.g., a chicken) that has been vaccinated with either one or two doses of 0.25 –

5 0.6 mL per dose of said vaccine. In one such embodiment, the concentration process includes diafiltration against a buffered solution in order to remove low molecular weight contaminants.

10 The process for making a *C. perfringens alpha* toxoid vaccine of the present invention can further comprise mixing the *C. perfringens alpha* toxoid supernatant with an adjuvant. In one such embodiment, the *C. perfringens alpha* toxoid supernatant is mixed in a water-in-oil emulsion. In a particular embodiment of this type, the water-in-oil emulsion is prepared with 70% oil phase and 30% aqueous phase.

15 The *C. perfringens* cells employed in the process can be from a single *C. perfringens* Type cell. In a particular embodiment of this type, the single *C. perfringens* Type cell is a *C. perfringens* Type A cell. In an alternative embodiment, the single *C. perfringens* Type cell is a *C. perfringens* Type C cell.

20

These and other aspects of the present invention will be better appreciated by reference to the following Detailed Description.

25 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides unique vaccines against *C. perfringens* that are both safe and effective for the prevention of clostridial diseases in animals. In a particular embodiment, the administration of a vaccine of the present invention to a female animal subject results in both the immunization of the female animal, and the development of antibodies that can be passively transferred to her subsequently born progeny. In one embodiment the present invention provides a vaccine that comprises a specific, minimum amount of an *alpha* toxoid of a single *C. perfringens* Type that is effective against harmful *C. perfringens* infections. In a particular embodiment, the vaccine comprises a safe and immunologically

30

35

5 effective combination of an *alpha* toxoid of the present invention and a pharmaceutically acceptable adjuvant.

The vaccines of the present invention can be used to protect against any condition or disease in which *C. perfringens* plays a role. Such diseases
10 include clostridial diseases. In one embodiment of this type, the clostridial disease is a clostridial enteric disease. Therefore, in a particular embodiment, the present invention provides vaccines that are effective for the prevention of the clostridial enteric disease in poultry known as necrotic enteritis. Other disease syndromes also may be prevented by the
15 vaccines of the present invention and include, but are not limited to, clostridia-related hepatitis, cholangiohepatitis, and gangrenous dermatitis.

The present invention discloses that a vaccine comprising a specific
20 minimal amount of *alpha* toxoid (*i.e.*, having a specific minimal TCP) obtained from a single *C. perfringens* Type, protects the progeny of the vaccinated female animal subject from clostridial diseases such as necrotic enteritis, regardless of whether any additional lethal toxins are expressed by a challenge *C. perfringens*. The present invention further
25 discloses a vaccine that elicits a specific minimal anti-*alpha* toxin response from the vaccinated female animal, which also protects the progeny of that vaccinated female animal subject from clostridial diseases, regardless of whether any additional lethal toxins are expressed by a naturally occurring *C. perfringens*. The vaccines of the present invention also may be
30 administered with an acceptable adjuvant.

As exemplified below, vaccinating hens with a vaccine derived from an inactivated *C. perfringens* Type A isolate that expresses an *alpha* toxin, but not a corresponding *beta* 2 toxin, unexpectedly, led to the passive
35 immunization of the three week-old progeny chicks against a challenge from a *C. perfringens* strain that expressed both the *alpha* toxin and the

5 *beta* 2 toxin. Heretofore, there had been no evidence for such cross-
protection against these two distinct toxins. Therefore, the present
invention provides relatively simple vaccines that are capable of
stimulating a specific minimum amount of anti-*alpha* toxins and thereby,
protect against clostridial diseases, e.g., necrotic enteritis, regardless of
10 what other toxins the *C. perfringens* challenge strain may express.

Indeed, in spite of the multitude of toxins and other biologically active
proteins produced by *C. perfringens* that have been shown to have
pathogenic effects on animals, and the multiple citations in the literature on
15 the contributions of these various toxins and other proteins to the
pathology of necrotic enteritis, the unique vaccines disclosed herein
provide both a substantial immune response to *C. perfringens* in
vaccinated broiler hens, and passive immunity to their subsequently born
offspring.

20 Although the present invention is completely independent of any theory or
model, the results provided herein are consistent with the *C. perfringens*
alpha toxin being the antigenic component that is both necessary and
sufficient for protection against necrotic enteritis. While the *beta*, *beta* 2
25 and enterotoxins may be critical to the pathology of necrotic enteritis, the
results provided herein are consistent with the *alpha* toxoid being the only
toxoid necessary in a vaccine for necrotic enteritis. In addition, since
alpha toxin production is generally the highest in Type A strains, *C.*
perfringens Type A strains are particularly useful as a source of *C.*
30 *perfringens alpha* toxin. However, other *C. perfringens* Types also can be
successfully used, especially when genetic modification has been used to
increase the level of *alpha* toxin production in these other Types.

As used herein the following terms shall have the definitions set out below:
35 As used herein a "protective antigen" is an antigen that results in the
production of specific antibodies that impart protection against infection
and/or disease to the animal vaccinated with that antigen and/or her

5 progeny. A vaccine which contains such a protective antigen is termed "immunologically effective".

As used herein the term "antigenic fragment" in regard to a particular protein is a fragment of that protein that is antigenic. For example, an
10 antigenic fragment of an *alpha* toxin or an *alpha* toxoid is a fragment of the *alpha* toxin or *alpha* toxoid that is antigenic. As used herein, an antigenic fragment of an *alpha* toxin or an *alpha* toxoid can be any fragment of the *alpha* toxin or *alpha* toxoid, respectively, including large fragments that are missing as little as a single amino acid from the full-length protein. In a
15 particular embodiment an antigenic fragment of an *alpha* toxin or *alpha* toxoid contains between 6 and 120 amino acid residues. In addition, an antigenic fragment of a given *alpha* toxin can be obtained by a recombinant source, from a protein isolated from natural sources, or through chemical synthesis. Moreover, an antigenic fragment can be
20 obtained following the proteolytic digestion of an *alpha* toxin, *alpha* toxoid, or a fragment thereof, through recombinant expression, or alternatively, it can be generated *de novo*, e.g., through peptide synthesis.

As used herein an "inactive antigenic fragment" of a *C. perfringens alpha*
25 toxin is an antigenic fragment of a *C. perfringens alpha* toxin that retains at least one antigenic epitope, but does not possess sufficient catalytic activities of the *alpha* toxin to make it deleterious. Such inactive antigenic fragments may be used alone, or alternatively, can be incorporated into fusion proteins.

30 As used herein, the term "*alpha* toxoid" refers to any inactive *alpha* toxin, (e.g., an inactive full-length *alpha* toxin) but is not meant to limit in any way the particular means of inactivating an *alpha* toxin to produce that *alpha* toxoid. Such inactivating methodology includes: (i) chemical methods that
35 modify the intact protein, e.g., formaldehyde or glutaraldehyde treatment; (ii) physical methods, such as heating; (iii) enzymatic methods that alter the protein, such as a protease that cleaves the toxin into fragments; (iv)

5 recombinant methods, such as genetic engineering of the *alpha* toxin gene to remove or alter enzymatic regions of the protein, but retaining one or more antigenic epitopes (see e.g., US 5,817,317, the contents of which is hereby incorporated by reference in its entirety); and/or combinations of any or all of the above.

10

As used herein a *C. perfringens* "*alpha* toxoid supernatant" is a solution comprising inactivated *C. perfringens alpha* toxin, in which at least a majority of the cells that produced the toxin have been removed (*i.e.*, greater than 70% of the cells being removed, and in a particular
15 embodiment, greater than 90% of the cells being removed). In a particular embodiment, the inactivated *C. perfringens alpha* toxin had been secreted into the culture media by *C. perfringens* cells that had been added to and/or cultured/grown in that culture media, and then inactivated. In another embodiment, the inactivated *C. perfringens alpha* toxin includes the *C.*
20 *perfringens alpha* toxin associated with the cells, which had been liberated through cell lysis, and then inactivated. The means of preparing the "*alpha* toxoid supernatant" is in no way meant to be limited to any particular method of removing the cells or cell debris from the solution, and includes centrifugation, column chromatography, ultrafiltration, etc.

25

As used herein a "cell-free" solution is one in which greater than 90% of the cells from a culture have been removed. The means of preparing the "cell-free" solution is in no way meant to be limited to any particular method of removing the cells or cell debris from the solution, and includes
30 centrifugation, column chromatography, ultrafiltration, etc.

As used herein the term "single *C. perfringens* Type" refers to one *C. perfringens* Type, e.g., Type A or Type B or Type C etc., as opposed to multiple Types, e.g., Type A and Type B and Type C. Therefore, a cell,
35 supernatant, composition, preparation, vaccine, etc. comprising an *alpha* toxoid of a "single *C. perfringens* Type" is a cell, supernatant, composition, preparation, vaccine, etc. that contains *alpha* toxoid from only that one

5 specific *C. perfringens* Type and does not contain *alpha* toxoid from any other *C. perfringens* Type. On the other hand, such cells, supernatants, compositions, preparations, vaccines, etc. may contain other non-*alpha* toxoid components, including other *C. perfringens* toxoids, and/or adjuvants, and/or immune stimulants, etc.

10

As used herein an "antitoxin unit" or "A.U." of anti-*alpha* toxin antibody per mL of antisera is used interchangeably with "anti-*alpha* Toxin Neutralizing Test" units or "TNT" units and is defined by the ability of sera to neutralize the toxic effects of *alpha* toxin in a mouse bioassay. In this test, a known
15 amount of *alpha* toxin established by international standards [EU Pharmacopoeia 5.0.: 01/2005:0088, pp. 803-804] is mixed with serial dilutions of sera from vaccinated animals. The mixture is incubated one hour at room temperature and then injected intravenously into mice. The mice will survive if the toxin is completely neutralized by the sera,
20 otherwise they die. The antitoxin units or titer is determined as the reciprocal of the highest dilution of sera that neutralized the toxin.

As used herein the term "Total Combining Power" is abbreviated by "TCP" and is defined as described by Batty [*Toxin-Antitoxin Assay, Methods in Microbiology*, Chapter 8, Volume 5A (1971), ed. JR Norris and DW Ribbons]. In this assay, a specific volume of the *alpha* toxoid supernatant is contacted with a known quantity of antitoxin units. After providing a
25 suitable incubation period to allow the antitoxin and *alpha* toxoid to bind, e.g., one hour at room temperature, a known quantity of the *alpha* toxin is added. The remaining free antitoxin then is given a suitable period to bind with the *alpha* toxin, e.g., one hour at room temperature. The amount of free *alpha* toxin is then determined by adding a substrate to the solution to measure the enzymatic activity of the *alpha* toxin. Suitable substrates include red blood cells (particularly sheep red blood cells) and lecithin.
30 The *alpha* toxoid can then be quantified through a calculation based upon the amount of enzymatic activity determined. The greater the amount of
35

5 *alpha* toxoid present in the assay solution, the higher the amount of enzymatic activity measured in the assay.

The terms "Type" and "biotype" are used interchangeably herein, and refer to the particular phenotype of a *C. perfringens* based on expression of various toxin genes. *Clostridium perfringens* is divided into types based on production of the four major toxins, *alpha*, *beta*, *epsilon* and *iota*. *C. perfringens* Type A produces *alpha* toxin; Type B produces *alpha*, *beta* and *epsilon* toxins; Type C produces *alpha* and *beta* toxins, Type D produces *alpha* and *epsilon* toxins, Type E produces *alpha* and *iota* toxins.

10 As many as 17 exotoxins of *C. perfringens* have been described. A biotype of *C. perfringens* is a classification based on production of some or all of the additional clostridial toxins and/or enzymes. For examples an enterotoxigenic pathotype of *C. perfringens* Type A may produce *theta* and *mu* toxins in addition to the *alpha* toxin.

20 As used herein, a multivalent vaccine is a vaccine that comprises two or more different antigens. In a particular embodiment of this type, the multivalent vaccine stimulates the immune system of the recipient against two or more different pathogens.

25 The terms "adjuvant" and "immune stimulant" are used interchangeably herein, and are defined as one or more substances that cause stimulation of the immune system. In this context, an adjuvant is used to enhance an immune response to one or more vaccine antigens. An adjuvant may be administered to the target animal before, in combination with, or after the administration of the vaccine. Adjuvants of the present invention may be obtained from any of a number of sources including from natural sources, recombinant sources, and/or be chemically synthesized, etc. Examples of chemical compounds used as adjuvants include, but are not limited to

30 aluminum compounds, metabolizable and non-metabolizable oils, block polymers, ISCOM's (immune stimulating complexes), vitamins and minerals (including but not limited to: vitamin E, vitamin A, selenium, and

35

5 vitamin B12), Quil A (saponins), and CARBOPOL®. Additional examples of adjuvants, that sometimes have been referred to specifically as immune stimulants, include, bacterial and fungal cell wall components (e.g., lipopolysaccharides, lipoproteins, glycoproteins, muramylpeptides, *beta*-1,3/1,6-glucans), various complex carbohydrates derived from plants (e.g.,
10 glycans, acemannan), various proteins and peptides derived from animals (e.g., hormones, cytokines, co-stimulatory factors), and novel nucleic acids derived from viruses and other sources (e.g., double stranded RNA, CpG). In addition, any number of combinations of the aforementioned substances may provide an adjuvant effect, and therefore, can form an adjuvant of the
15 present invention.

As used herein an "anti-*alpha* toxin" is an antibody (monoclonal or polyclonal) that binds to *alpha* toxin. Antibodies to an *alpha* toxin can be measured by a TNT assay as described above. Alternatively, antibodies
20 can be detected by their ability to block the hemolytic effect of the *alpha* toxin. In a hemolysis inhibition assay, a known quantity of *alpha* toxin, sufficient to catalyze complete lysis of a given preparation of sheep red blood cells, is mixed with serial dilutions of sera and incubated for one hour at 36 ± 2 °C. The mixture is then incubated with 0.5% sheep red
25 blood cells for three hours at 36 ± 2 °C. When antibody binds to the *alpha* toxin, the toxin is unable to hemolyze the red blood cells. The titer is determined by the reciprocal of the highest dilution of sera that results in no hemolysis. In a similar assay, the ability of antibodies bound to *alpha* toxin to inhibit phospholipase activity can be measured by determining the
30 highest dilution of antisera that blocks the enzymatic cleavage of lecithin.

As used herein the term "polypeptide" is used interchangeably with the term "protein" and is further meant to encompass peptides. Therefore, as used herein, a polypeptide is a polymer of two or more amino acids joined
35 together by peptide linkages. Polypeptides of the present invention include naturally occurring proteins; recombinant proteins; chemically synthesized proteins; fragments of any of the naturally occurring,

recombinant, or chemically synthesized proteins; and fusion proteins that comprise any of the naturally occurring, recombinant, and/or chemically synthesized proteins, and/or any of their fragments. Preferably, the term polypeptide is used to denote a polymer comprising twenty or more amino acid residues joined together by peptide linkages, whereas the term peptide is used to denote a polymer comprising two to twenty amino acid residues joined together by peptide linkages.

A "heterologous nucleotide sequence" as used herein is a nucleotide sequence that is added by recombinant methods to a nucleotide sequence encoding a protein described herein, *e.g.*, an *alpha* toxin described herein, or encoding a fragment thereof (*e.g.*, an inactive antigenic fragment), to form a nucleic acid that is not naturally formed in nature. Such nucleic acids can encode fusion proteins. In addition, as used herein, a heterologous nucleotide sequence need not be a single contiguous nucleotide sequence, but can include multiple non-contiguous nucleotide sequences that have been combined with a nucleotide sequence encoding a polypeptide described herein, or a portion thereof. A heterologous nucleotide sequence can comprise non-coding sequences including restriction sites, regulatory sites, promoters and the like. In still another embodiment the heterologous nucleotide can function as a means of detecting a nucleotide sequence described herein. Described herein are heterologous nucleotide sequences that when combined with nucleotide sequences encoding a polypeptide described herein or a fragment thereof, are necessary and sufficient to encode all of the fusion proteins described herein.

As used herein a vaccine "consisting essentially of" or that "consists essentially of" a single *C. perfringens* Type *alpha* toxoid, and/or antigenic fragment of the *C. perfringens alpha* toxoid, and/or inactive antigenic fragment of the corresponding *alpha* toxin is a vaccine that contains an immunologically effective amount of the single *C. perfringens* Type *alpha* toxoid, and/or antigenic fragment of the *C. perfringens alpha* toxoid, and/or

5 inactive antigenic fragment of the corresponding *alpha* toxin, to protect
against a clostridial disease, but does not contain an immunologically
effective amount of any other antigen known to protect against a clostridial
disease such as another *C. perfringens* antigen, or an alternative *C.*
10 *perfringens* Type *alpha* toxin, *alphatoxoid*, or fragment thereof. Such
vaccines may further include antigens related to other diseases such as
viral antigens from infectious bursal disease virus, reovirus, and Newcastle
disease virus; bacterial antigens from *E. coli*, *Salmonella*, and
15 *Campylobacter*; and a parasite antigens such as one from *Eimeria*.

15 As used herein the term "about" when used in conjunction with a particular
dosage value signifies that the dosage value is within twenty percent of the
indicated value, e.g., a dosage of about 0.5 mL can comprise between 0.4
mL and 0.6 mL.

20 Isolation of *C. Perfringens* Type A

C. perfringens isolates, such as *C. perfringens* type A, can be obtained
from fecal samples and/or intestinal scrapings of infected animals. The
samples/scraping can be streaked on blood agar plates, incubated
anaerobically at $35 \pm 1^\circ\text{C}$ for 24-48 hours, and colonies that resemble *C.*
25 *perfringens* type A are individually picked. To confirm their identity as *C.*
perfringens type A isolate(s), the selected colonies can be further tested
for characteristic *C. perfringens* type A biochemical properties, including
genetic makeup.

30 The presence of the *alpha* toxin gene in the isolate can be determined by
genetic analysis, e.g., by PCR. The expression of *alpha* toxin can be
shown by its lecithinase activity in an assay using egg yolk and/or by a
hemolysis assay employing sheep red blood cells. In a particular
embodiment, *C. perfringens* isolates that express a high level of *alpha*
35 toxin are used in the preparation of a vaccine of the present invention. A
selected *C. perfringens* isolate(s) can be grown anaerobically in nutrient

- 5 broth for 4-24 hours. The culture can be inactivated with, e.g., formalin, concentrated and blended into such a vaccine.

C. Perfringens Toxins

- 10 *Alpha* toxin – *Alpha* toxin is produced by all types of *C. perfringens*. *Alpha* toxin is a multifunctional phospholipase C that can split lecithin, forming phosphorylcholine and a diglyceride. When administered intravenously, *alpha* toxin has been shown to be lethal to mice. *Alpha* toxin is also markedly hemolytic. However, the susceptibility of red blood cells can
15 vary greatly depending on the species of animal used as the source of the red blood cells. *Alpha* toxin also brings about the aggregation of platelets, the lysis of platelets, leukocytes, and other body cells, as well as causing an increase in vascular permeability.

- 20 *Beta* toxin – *Beta* toxin is produced by *C. perfringens* Types B and C. The *beta* toxin is responsible for the inflammation of the intestine and the wholesale loss of mucosa, as well as the inhibition of intestinal movement. The *beta* toxin is a protein having a molecular weight of 35 kDa and is much more susceptible to proteolytic enzymes such as trypsin, than the
25 other *C. perfringens* toxins. *Beta* toxin has been reported to be lethal to animals, with mice being the most sensitive and chickens being the least sensitive.

- 30 *Beta 2* toxin – The *beta 2* toxin is the most recently discovered of the *C. perfringens* toxins. Despite their similar names, the amino acid sequences of the *beta 2* toxin and the *beta* toxin show no homology. The literature has shown a strong association between *beta 2* toxin and necrotic enteritis in certain animals [Garmory *et al.*, *Epidemiol. Infect.* 124:61-67 (2000), Herholz *et al.*, *J. Clin. Morco*, Feb:358-361 (1999)]. The *beta 2* toxin has a
35 molecular weight of 28 kDa. *Beta 2* toxin has been found to be lethal to mice and cytotoxic to certain cell lines, inducing rounding of the cells and lysis without affecting the actin cytoskeleton [Manteca *et al.*, *Vet. Microb.*

- 5 86:191-202 (2002), Schotte *et al.*, *J. Vet Med B* 51:423-416 (2004),
Gilbert *et al.*, *Gene* 203:65-73 (1997)].

Enterotoxin – Enterotoxin is typically produced by *C. perfringens* Type A strains. The presence of the enterotoxin has been traditionally used to
10 delineate enteric disease associated strains from those which are associated with tissue gas gangrene. Strains which cause gas gangrene do not typically have enterotoxin. The enterotoxin is a heat sensitive protein that has a molecular weight of 34 kDa. The lethal dose for mice is about 10 micrograms. The initial interaction of the enterotoxin is to form
15 pores in the host cell, followed by altered permeability of the cell, inhibition of macromolecular synthesis, cytoskeletal disintegration, and finally, lysis [see, Songer, *Clin. Micro. Rev.*, 9(2):216-234 (1996)]. Enterotoxin effectuates the reversal of net transport in the cells of the intestines.

20 *Epsilon* toxin – *Epsilon* toxin is produced by *C. perfringens* Types B and D. *Epsilon* toxin is secreted as a protoxin that is converted by endogenous trypsin into an extremely potent neurotoxin. When administered intravenously, *Epsilon* toxin can be extremely lethal to mice. *Epsilon* toxin has a high affinity for neural tissue and has the effect of causing vascular
25 permeability. *Epsilon* toxin also causes permeability of the gut wall allowing large molecules, including itself, to enter the bloodstream. The *epsilon* toxin then progresses through the bloodstream to the brain where it disrupts the osmotic balance. This disruption of osmotic balance in the brain results in the neurological signs observed prior to the death of the
30 afflicted animal.

Kappa toxin – *Kappa* toxin is a collagen-hydrolyzing enzyme produced by *C. perfringens* Types A, D, E, and some Types of B and C. *Kappa* toxin has a molecular weight of 80 kDa and is lethal to mice. Intravenous
35 injection of *kappa* toxin to a mouse produces death within one hour due to the intense hemorrhaging of the lungs.

5 *Theta toxin* – Most strains of *C. perfringens* produce *theta* toxin. *Theta* toxin is 74 kDa protein responsible for the clear zones of hemolysis seen around colonies on blood agar plates. Purified *theta* toxin is extremely lethal to mice, producing death in a matter of minutes. *Theta toxin* is inhibited by certain steroids, with cholesterol being the most potent
10 inhibitor.

Passive Immunity

The present invention includes a vaccine comprised of a safe and immunologically effective preparation of a minimum amount of an antigen
15 of the present invention, e.g., an *alpha* toxoid, for the vaccination of non-human females, particular fertile and/or pregnant females, who can then transfer the effect of the vaccine to their newborn. Such transfer of immunity from mother to progeny is termed "passive immunity". Passive immunity can be accomplished *inter alia* through the ingestion of
20 colostrums, as occurs in mammals or the absorption of antibody into the bloodstream from the egg yolk, as occurs in poultry. In addition, as disclosed herein, poultry may consume antibodies *in ovo*, which results in raising the level of circulating systemic antibodies.

25 As demonstrated herein, passively transferring a specific amount of anti-*alpha* toxin to the neonatal animal protects neonates against a virulent *Clostridium perfringens* challenge. The extent of protection, as disclosed below, was completely unexpected, as heretofore, it had been believed that the gut had to be bathed with antibodies in order to significantly
30 protect against an oral *C. perfringens* type A challenge. Similarly, it is quite surprising that a correlation would exist between maternal antibody transfer of mucosal immunity through the ingestion of colostrum in the neonatal mammal and the absorption of maternal antibody in the egg. As demonstrated below for chickens, anti-*alpha* toxin antibodies are
35 absorbed into the blood stream *in ovo*. Moreover, the present invention discloses that inducing a specific, defined minimum anti-*alpha* toxin antibody titer in the bloodstream of the hen is sufficient to protect the

5 vaccinated offspring of that hen from a *C. perfringens* type A challenge performed weeks after the birth of those offspring.

Active Immunity

10 The present invention includes for the vaccination of chicken chicks (e.g., broiler chicks) and/or turkey poults to provide active immunity against necrotic enteritis, necrotic dermatitis and gangrenous dermatitis. The chicks and/or poults are vaccinated early in life, at about day one of age or slightly older (within the first week of life) with a single or two doses of the vaccine. Appropriate vaccine dosages for achieving active immunity can
15 vary from about 0.05 mL to about 0.5 mL. In a particular embodiment the vaccine dosage is about 0.05 mL to about 0.1 mL.

Cell Culture

Clostridium perfringens secretes *alpha* toxin into the media during growth.
20 After inactivation and removing at least a majority of the cells from the growth media, the resulting solution is referred to as an *alpha* toxoid supernatant. The cells are generally removed to minimize extraneous antigens in the vaccine which might otherwise promote reactivity and lessen the immune response. However, there is also a finite amount of
25 cell-associated *alpha* toxin. Therefore, the *alpha* toxin antigen may be derived from the cells and/or the media, in either concentrated or non-concentrated form.

C. perfringens may be grown in any appropriate vessel including flasks,
30 bottles, jugs, or mechanical fermenters. Fermentations may be monitored during growth so as to harvest the fermenter when the *alpha* toxin production is at its peak. Typical methods include affinity chromatography, gel electrophoresis (PHAST system, etc.), immuno assays, hemolysin and lecithinase activity assays. The cell culture fluid or cellular extract can be
35 inactivated with formaldehyde (0.1-2.0%) or a combination of formaldehyde and heat. Other chemicals that are typically used for protein denaturing and may also be used include, but are not limited to:

5 glutaraldehyde, phenol, various detergents such as Triton X-100, Sodium
dodecyl sulfate (SDS), and alcohols. Residual formaldehyde levels may
be monitored during inactivation so as to keep an optimal level without
over or under toxoiding. Typical methods for measuring free formaldehyde
are listed in the European Pharmacopoeia (01/2005:20418) or the 9 CFR
10 (113.100). Similar methods are available for measuring other types of
toxin inactivants. In certain instances the *alpha* toxin is deliberately under-
toxoided at this point in order to minimize denaturation of epitopes critical
for the development of antitoxins, and then further treated for detoxification
at a later point in the process. Other suitable chemical or biological agents
15 capable of inactivating the toxin may be also used such as glutaraldehyde,
phenol, various detergents such as Triton X-100, Sodium dodecyl sulfate
(SDS), and alcohols.

The resulting *alpha* toxoid may be stored for a period of time prior to any
20 additional processing, without detrimental effects. Typically, optimal
storage is at 2-8 °C. However, inactivated clostridial toxoids are extremely
stable and may also be stored at higher temperature. For periods of
storage longer than 6 months and higher than 8 °C in temperature, it may
be advisable to retest the potency of the toxoid by a Total Combining

25 Power test (TCP), or another similar immunological assay to determine the
immunogenic stability of the toxoid.

The cells may be removed from the inactivated culture medium by
30 centrifugation and/or filtration to obtain the toxoid supernatant. Removal of
the cells serves to reduce tissue reactivity that can be caused by the cell
components, whereas, removing extraneous antigens from the preparation
helps the immune response to focus on the toxoid component of the
vaccine.

35 The inactivated culture medium may be concentrated by any of a number
of means including ultrafiltration (preferably using ultrafiltration membranes

of not greater than 30,000 molecular weight cut-off) or by lyophilization. The concentration process may include diafiltration against an aqueous solution (e.g., phosphate buffered saline) in order to remove low molecular weight contaminants from the preparation. The concentrated fluid may be re-treated one or more times with either formaldehyde and/or heat until a suitable assay indicates that the fluid is free from residual toxicity. Such assays include a mouse bioassay, *i.e.*, injecting the fluid into mice and observing its effect on the mice; or measuring hemolysin activity, or lecithinase activity, etc.

The pH of the solution may have to be adjusted prior to blending to ensure optimal binding to adjuvants, emulsification with oils, and/or stability of solution. The isoelectric point (pI) of the *alpha* toxin is approximately 5.5 [Smith *et al.*, *The Pathogenic Anaerobic Bacteria*, (3rd Ed.) Charles Thomas Publishers, p. 116 (1984)]. Adjustment of the pH of the toxoid solution will alter the net charge on the protein, which is advantageous for enhancement of binding to certain adjuvants, such as aluminum adjuvants. The pH may also be adjusted to a level which increases the stability of the *alpha* toxoid for storage over a prolonged period of time. For example, proteins are more likely to precipitate out of solution at their pI, but are usually stable at 1 pH unit above or below this value.

Nucleic Acids Encoding the Polypeptides of the Present Invention

A nucleic acid, such as a cDNA, that encodes a polypeptide described herein, can be used to generate recombinant bacterial host cells that express a protein and/or antigen of the present invention, e.g., the *alpha* toxin. Such recombinant host cells can be inactivated, *i.e.*, converted to bacterins, and used in immunogenic compositions such as vaccines.

In addition, obtaining and/or constructing a nucleic acid that encodes a polypeptide described herein, including those encoding an *alpha* toxin described herein, or an inactive antigenic fragment thereof, may facilitate the production of the *alpha* toxin, *alpha* toxoid or fragments

5 thereof. The *alpha toxin*, *alpha* toxoid and/or antigenic fragments of either are useful for making certain vaccines of the present invention.

Accordingly, the present invention includes nucleic acid constructs that allow for the expression and isolation of the proteins and/or antigenic
10 fragments of the present invention. Sequences for such nucleic acids and corresponding recombinant proteins of the antigens to be used in this aspect of the present invention are well known to the skilled artisan. A small sampling of the antigens that can be used in the vaccines of the present invention, along with their GenBank accession number, and a
15 scientific article disclosing their amino acid sequences are provided below.

EXAMPLES OF ANTIGENS THAT CAN BE USED IN VACCINES

<u>SOURCE</u>	<u>ACCESSION</u>	<u>¹ARTICLE</u>
<u>Antigen</u>	<u>No.</u>	
<u>C. PERFRINGENS</u>		
<i>alpha toxin</i>	CAA35186	Saint-Joanis <i>et al.</i> , Mol. Gen. Genet. 219 (3):453-460 (1989)
<i>beta toxin</i>	CAA58246	Steinthorsdottir <i>et al.</i> , FEMS Microbiol. Lett. 130 (2-3): 273-278 (1995)
<i>beta 2 toxin</i>	NP_150010	Shimizu <i>et al.</i> , Proc. Natl. Acad. Sci. U.S.A. 99 (2): 996-1001 (2002)
enterotoxin	BAE79112	Miyamoto <i>et al.</i> , J. Bacteriol. 188 (4): 1585-1598 (2006)
<i>epsilon toxin</i>	AAA23236	Havard <i>et al.</i> , FEMS Microbiol. Lett. 97: 77-82 (1992)
<i>iota toxin</i>	CAA51959	Perelle <i>et al.</i> , Infect. Immun. 61 (12): 5147-5156 (1993)
kappa toxin	NP_561089	Shimizu <i>et al.</i> , Proc. Natl. Acad. Sci. U.S.A. 99 (2): 996-1001 (2002)
<i>lambda toxin</i>	CAA35187	Saint-Joanis <i>et al.</i> , Mol. Gen. Genet. 219 (3):453-460 (1989)
<i>theta toxin</i>	NP_561079	Shimizu <i>et al.</i> , Proc. Natl. Acad. Sci. U.S.A. 99 (2): 996-1001 (2002)
<u>C. DIFFICILE</u>		
A toxin	A37052	Wren <i>et al.</i> , FEMS Microbiol. Lett. 70: 1-6 (1990)
B toxin	CAA43299	von Eichel-Streiber <i>et al.</i> , Mol. Gen. Genet. 233: (1-2), 260-268 (1992)

¹ The sequences provided in these articles are hereby incorporated by reference.

<u>C. SEPTICUM</u>		
<i>alpha</i> toxin	AAB32892	Ballard <i>et al.</i> , <i>Infect. Immun.</i> 63 (1): 340-344 (1995)
<u>C. NOVYI</u>		
<i>alpha</i> toxin	AAB27213	Ball <i>et al.</i> , <i>Infect. Immun.</i> 61 (7): 2912-2918 (1993)

The nucleic acids encoding protein antigens that can be used in the vaccines of the present invention can further contain heterologous nucleotide sequences. To express a recombinant protein in a host cell, an expression vector can be constructed comprising the corresponding cDNA. The disclosure therefore, includes expression vectors containing nucleic acids encoding recombinant proteins of the present invention, including variants thereof.

Due to the degeneracy of nucleotide coding sequences, other nucleotide sequences which encode substantially the same amino acid sequence as a nucleic acid encoding a polypeptide described herein may be used in the practice of the present invention. These include, but are not limited to, allelic genes, homologous genes from other strains, and/or those that are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Host cells comprising the expression vectors of the present invention are also included. One commonly employed host cell, is an *E. coli* cell.

General methods for the cloning of cDNAs and expression of their corresponding recombinant proteins have been described [see Sambrook and Russell, *Molecular Cloning, A laboratory Manual*, 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor L.I. (2000)].

In addition, any technique for mutagenesis known in the art can be used to modify a native *alpha* toxin, including but not limited to, *in vitro* site-directed mutagenesis [Hutchinson *et al.*, *J. Biol. Chem.*, 253:6551 (1978); Zoller and Smith, *DNA*, 3:479-488 (1984); Oliphant *et al.*, *Gene*, 44:177 (1986); Hutchinson *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 83:710 (1986);

Wang and Malcolm, *BioTechniques* 26:680-682 (1999) the contents of which are hereby incorporated by reference in their entireties]. The use of TAB@ linkers (Pharmacia), etc. and PCR techniques also can be employed for site directed mutagenesis [see Higuchi, "Using PCR to Engineer DNA", in PCR Technology: Principles and Applications for DNA Amplification, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70 (1989)].

Polypeptides

Described herein are isolated and/or recombinant polypeptides, including, the *alpha* toxins and *alpha* toxoids described herein, strain variants thereof, inactive antigenic fragments thereof, and fusion proteins thereof. In addition, polypeptides containing altered sequences in which functionally equivalent amino acid residues are substituted for those within the wild type amino acid sequence resulting in a conservative amino acid substitution are also included by the present invention.

For example, one or more of these amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.

For example, the nonpolar amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine and lysine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Particularly preferred conserved amino acid exchanges are:

Particularly preferred conserved amino acid exchanges are:

- (a) Lys for Arg or *vice versa* such that a positive charge may be maintained;
- (b) Glu for Asp or *vice versa* such that a negative charge may be maintained;
- (c) Ser for Thr or *vice versa* such that a free -OH can be maintained;
- (d) Gln for Asn or *vice versa* such that a free NH₂ can be maintained; and
- (e) Ile for Leu or for Val or *vice versa* as roughly equivalent hydrophobic amino acids.

All of the polypeptides described herein, including the antigenic fragments, can be part of a fusion protein. In a specific embodiment, a fusion polypeptide is expressed in a prokaryotic cell. Such a fusion protein can be used for example, to enhance the antigenicity of an antigen or fragment thereof, to lower or remove its toxicity without negating its antigenicity, or to isolate an antigen described herein. Isolation of the fusion protein in the latter case can be facilitated through the use of an affinity column that is specific for the protein/peptide fused to the antigen. Such fusion proteins include: a glutathione-S-transferase (GST) fusion protein, a maltose-binding protein (MBP) fusion protein, a FLAG-tagged fusion protein, or a poly-histidine-tagged fusion protein. Specific linker sequences such as a Ser-Gly linker can also be part of such a fusion protein.

Indeed, the expression of a fusion polypeptide can facilitate stable expression, and/or allow for purification based on the properties of the fusion partner. Thus the purification of the recombinant polypeptides of the present invention can be simplified through the use of fusion proteins having affinity Tags. For example, GST binds glutathione conjugated to a solid support matrix, MBP binds to a maltose matrix, and poly-histidine chelates to a Ni-chelation support matrix [see Hochuli *et al.*, *Biotechnology* 6:1321-1325 (1998)].

The fusion protein can be eluted from the specific matrix with appropriate buffers, or by treating with a protease that is specific for a cleavage site

that has been genetically engineered in between an *alpha* toxin, for example, and its fusion partner. Alternatively, an *alpha* toxin can be combined with a marker protein such as green fluorescent protein [Waldo *et al.*, *Nature Biotech.* 17:691-695 (1999); U.S. Patent No. 5,625,048 and WO 97/26333, the contents of which are hereby incorporated by reference in their entireties].

Alternatively or in addition, other column chromatography steps (*e.g.*, gel filtration, ion exchange, affinity chromatography etc.) can be used to purify the natural or recombinant polypeptides described herein (see below). In many cases, such column chromatography steps employ high performance liquid chromatography or analogous methods in place of the more classical gravity-based procedures.

In addition, the polypeptides described herein, including the *alpha* toxins and inactive antigenic fragments thereof can be chemically synthesized [see *e.g.*, *Synthetic Peptides: A User's Guide*, W.H. Freeman & Co., New York, N.Y., pp. 382, Grant, *ed.* (1992)].

General Polypeptide Purification Procedures

Generally, initial steps for purifying a polypeptide described herein can include salting in or salting out, *e.g.*, in ammonium sulfate fractionations; solvent exclusion fractionations, *e.g.*, an ethanol precipitation. In addition, high speed ultracentrifugation may be used either alone or in conjunction with other extraction techniques.

Generally good secondary isolation or purification steps include solid phase absorption using calcium phosphate gel, hydroxyapatite, or solid phase binding. Solid phase binding may be performed through ionic bonding, with either an anion exchanger, such as diethylaminoethyl (DEAE), or diethyl [2-hydroxypropyl] aminoethyl (QAE) SEPHADEX or

5 cellulose; or with a cation exchanger such as carboxymethyl (CM) or
sulfopropyl (SP) SEPHADEX or cellulose. Alternative means of solid
phase binding includes the exploitation of hydrophobic interactions e.g.,
the use of a solid support such as phenylSephadex and a high salt buffer;
affinity-binding immuno-binding, using e.g., an *alpha* toxin-antibody bound
10 to an activated support. Other solid phase supports include those that
contain specific dyes or lectins etc.

A further solid phase support technique that is often used at the end of the
purification procedure relies on size exclusion, such as SEPHADEX and
15 SEPHAROSE gels. Alternatively, a pressurized or centrifugal membrane
technique, using size exclusion membrane filters may be employed.
Oftentimes, these two methodologies are used in tandem.

Solid phase support separations are generally performed batch-wise with
20 low-speed centrifugation, or by column chromatography. High
performance liquid chromatography (HPLC), including such related
techniques as FPLC, is presently the most common means of performing
liquid chromatography. Size exclusion techniques may also be
accomplished with the aid of low speed centrifugation. In addition size
25 permeation techniques such as gel electrophoretic techniques may be
employed. These techniques are generally performed in tubes, slabs or
by capillary electrophoresis.

Almost all steps involving polypeptide purification employ a buffered
30 solution. Unless otherwise specified, generally 25-100 mM concentrations
of buffer salts are used. Low concentration buffers generally imply 5-25
mM concentrations. High concentration buffers generally imply
concentrations of the buffering agent of between 0.1 – 2.0 M
concentrations. Typical buffers can be purchased from most biochemical
35 catalogues and include the classical buffers such as Tris, pyrophosphate,
monophosphate and diphosphate and the Good buffers such as Mes,
Hepes, Mops, Tricine and Ches [Good *et al.*, *Biochemistry*, **5**:467 (1966);

5 Good and Izawa, *Meth. Enzymol.*, 24B:53 (1972); and Ferguson and Good, *Anal. Biochem.*, 104:300 (1980)].

Materials to perform all of these techniques are available from a variety of commercial sources such as Sigma Chemical Company in St. Louis, Missouri.

10

Vaccine Components

C. Perfringens Alpha Toxoid: In particular embodiments it is advantageous for the animal vaccine to contain the minimum amount of the *alpha toxoid* required for protection against necrotic enteritis. That level was
15 determined to be 2 Total Combining Power units (TCP) per dose under the particular conditions exemplified below. TCP units are set based upon international standards [Batty, *Toxin-Antitoxin Assay, Methods in Microbiology*, Chapter 8, Volume 5A (1971) ed. JR Norris and DW Ribbons] and the vaccines of the present invention can be readily blended
20 to have the desired potency. Less than 2 TCP units may be used, even under these conditions, if the vaccine further comprises immune stimulants. In any case, it is preferable that the vaccine elicit 4 or more antitoxin units per mL of animal sera.

25 Quantifying Alpha Toxoid: It is generally desirable to quantify the *alpha* toxoid to ensure that optimal levels are included in the vaccine. One conventional method of quantifying toxoids employs the Total Combining Power (TCP) test. In this assay, a specific volume of the *alpha* toxoid supernatant is contacted with a known quantity of antitoxin units. After
30 providing a suitable incubation period to allow the antitoxin and *alpha* toxoid to bind, e.g., 0.5 - 2 hours, a known quantity of the *alpha* toxin is added. The remaining free antitoxin then is given a suitable period to bind with the *alpha* toxin. The amount of free *alpha* toxin is then determined by adding to the solution a substrate for the phospholipase C activity of the
35 *alpha* toxin. Suitable substrates include red blood cells (particularly sheep red blood cells) and lecithin. The *alpha* toxoid can then be quantified through a calculation based upon the amount of phospholipase C activity.

5 The greater the amount of *alpha* toxoid present in the assay solution, the greater the amount of phospholipase C activity measured in the assay. Alternatively, the determination may be made without measuring the phospholipase C activity, *e.g.*, any competitive antibody binding analysis may be used, including incorporating a chromatography step, enzyme
10 linked immunosorbant assay (ELISA), or competitive binding analysis by a Biacore instrument or the like.

Additional Antigens: Clostridial diseases often occur as mixed infections and therefore the addition of other clostridial toxoids may further reduce pathology and clinical signs. Non-limiting examples of other clostridial
15 toxoids from organisms which are known to cause gastric enteritis, including those from *C. perfringens*, that may be added to a vaccine of the present invention to increase potency against mixed infections include: *C. perfringens beta toxin*, *beta 2 toxin*, *theta toxin*, *epsilon toxin*, enterotoxin, *kappa toxin*, *lambda toxin* and *iota toxin*; *C. sordellii* hemorrhagic toxin (HT) and lethal toxin (LT), *C. difficile* A and B toxins; *C. septicum alpha* toxin; and *C. novyi alpha* (A) and *beta* (B) toxins.
20

Antigens from other bacteria, viruses, fungi, or parasites may also be
25 included in the vaccines of the present invention. Such antigens include other toxins or toxoids, bacteria and/or extracts from bacteria; fungi and/or extracts from fungi; viruses and/or viral proteins; and/or parasites or proteins from parasites. Appropriate viral, bacterial, and parasitic antigens from the sources provided herein are well known in the art.

30 Non-limiting examples of bacterial organisms are: *Escherichia coli*, *Camplobacter spp.*, *Pasteurella spp.*, *Staphylococcus spp.*, *Streptococcus spp.*, *Enterococcus spp.*, *Chlamydia*, *Erysipelas spp.* *Pasteurella*, *Bordetella*, and *Ornithobacterium*.

35 Non-limiting examples of related toxins are: Gram negative bacteria lipopolysaccharide (LPS), which is known to enhance the immunological

5 response of vaccines and thus improve the production of antitoxins to the
alpha toxin of *C. perfringens* and mycotoxins.

Non-limiting examples of appropriate viruses are: Coronavirus, Rotavirus,
Astrovirus, Enteroviruslike virus, Torovirus, Adenovirus, Reovirus,
Birnavirus, Herpesvirus, Paramyxovirus, Picornavirus, Mareks Disease
10 Virus, Hemorrhagic Enteritis Virus, and Newcastle Disease Virus.

Non-limiting examples of parasites are: Coccidia, the *Eimeria* species for
example, and Cryptosporidia, [see, US 2004/0018215A1, the contents of
which are hereby incorporated by reference in their entireties].

15

Adjuvants

Adjuvants are also useful for improving the immune response and/or
increasing the stability of vaccine preparations. Adjuvants are typically
described as non-specific stimulators of the immune system, but also can
20 be useful for targeting specific arms of the immune system. One or more
compounds which have this activity may be added to the vaccine.
Therefore, particular vaccines of the present invention further comprise an
adjuvant. Examples of chemical compounds that can be used as
adjuvants include, but are not limited to aluminum compounds (e.g.,
25 aluminum hydroxide), metabolizable and non-metabolizable oils, mineral
oils including mannide oleate derivatives in mineral oil solution (e.g.,
MONTANIDE ISA 70 from Seppic SA, France), and light mineral oils such
as DRAKEOL 6VR, block polymers, ISCOM's (immune stimulating
complexes), vitamins and minerals (including but not limited to: vitamin E,
30 vitamin A, selenium, and vitamin B12) and CARBOPOL®.

Other suitable adjuvants, which sometimes have been referred to as
immune stimulants, include, but are not limited to: cytokines, growth
factors, chemokines, supernatants from cell cultures of lymphocytes,
35 monocytes, cells from lymphoid organs, cell preparations and/or extracts
from plants, bacteria or parasites (*Staphylococcus aureus* or
lipopolysaccharide preparations) or mitogens.

Generally, an adjuvant is administered at the same time as an antigen of the present invention. However, adjuvants can also, or alternatively be administered within a two-week period prior to the vaccination, and/or for a period of time after vaccination, *i.e.*, so long as the antigen, *e.g.*, an *alpha* toxoid, persists in the tissues.

Preparation of Vaccines

Processes for making the vaccines of the present invention are also provided. In one embodiment, the vaccine comprises blending a safe and immunologically effective combination of an antigen described herein, *e.g.*, an *alpha* toxoid supernatant of a single *C. perfringens* Type, and a pharmaceutically acceptable adjuvant. The amount of *alpha* toxoid can be quantified to contain at least 2 total combining power (TCP) units per dose of the vaccine. The *alpha* toxoid supernatant can be concentrated to minimize the dose size required to obtain at least 4.0 antitoxin units (A.U.) per mL of antisera from a vaccinated animal. The addition of other pharmaceutically acceptable immune modulation agents can reduce the TCP requirement to fall below 2 units per dose, so long as the vaccination still results in the requisite 4.0 A.U. of anti-*alpha* toxin antibody per mL of antisera from the vaccinated animal. In certain embodiments, the *C. perfringens alpha* toxoid is further purified from the *alpha* toxoid supernatants by such techniques as, but not limited to, concentration/ultrafiltration, chromatography and centrifugation.

Administration of Vaccines

Vaccines may be administered as a liquid, emulsion, dried powder and/or in a mist through any parenteral route, intravenously, intraperitoneally, intradermally, by scarification, subcutaneously, intramuscularly, or inoculated by a mucosal route, *e.g.*, orally, intranasally, as an aerosol, by eye drop, by *in ovo* administration, or implanted as a freeze dried powder.

Animal Subjects

The term "animal subject" refers to an animal species capable of being infected by a pathogenic bacterium, and in a particular embodiment includes humans. Appropriate animal subjects also include those in the wild, livestock (e.g., raised for meat, milk, butter, eggs, fur, leather, feathers and/or wool), beasts of burden, research animals, companion animals, as well as those raised for/in zoos, wild habitats and/or circuses.

In a particular embodiment an animal subject is a "food producing" animal. For purposes of the present invention, the term "food-producing" animal shall be understood to include all animals bred for consumption (e.g., turkeys, broiler chickens) or for consumables (e.g., dairy cows, egg-laying hens, and the like) by humans and/or other animals. A non-limiting list of such animals include avians such as poultry, *i.e.*, chickens, turkeys, geese, duck, ostriches, etc., bovines (e.g., cattle, dairy cows, buffalo), ovines (e.g., goats or sheep), porcines (e.g., swine, hogs or pigs), and equines (e.g., horses) etc.

In another embodiment, the animal subject is a companion animal. For purposes of the present invention, the term "companion" animal shall be understood to include housecats (feline), dogs (canine), rabbit species, horses (equine), rodents (e.g., guinea pigs, squirrels, rats, mice, gerbils, and hamsters), primates (e.g., monkeys) and avians, such as pigeons, doves, parrots, parakeets, macaws, canaries, and the like.

Other animals are also contemplated to benefit from the inventive vaccines, including marsupials (such as kangaroos), reptiles (such as farmed turtles), game birds, swans, ratites, and other economically important domestic animals.

The following examples are intended for exemplification of the present invention only and should not be construed to limit the scope of the invention in any way.

5

EXAMPLESEXAMPLE 1

10

EFFICACY OF VACCINE IN BROILER HENS
VACCINATED BY A SUBCUTANEOUS ROUTESummary

Vaccinating broiler hens by a subcutaneous route using a vaccine
15 comprising a single *C. perfringens* Type *alpha* toxoid (Type A) results in
(i) an immunogenic response in the vaccinated broiler hens, (ii) significant
anti-*alpha* toxoid antibody in the eggs of the vaccinated broiler hens, and
(iii) passive protection of the subsequently born offspring of the vaccinated
broiler hens.

20

Materials

C. Perfringens Type A *alpha* toxoid: *C. perfringens* Type A *alpha* toxoid is
prepared as follows: *C. perfringens* Type A culture is grown under
anaerobic conditions in a large scale fermenter (5000L) at a temperature
of 37 °C ± 2. During fermentation sodium hydroxide is added in order to
25 maintain a pH of 7.8 ± 2. Carbohydrate (dextrin) is also added during the
fermentation (up to 1% w/v) to promote growth. The culture is allowed to
grow for 3-6 hours. At the end of the growth period, formaldehyde solution
is added to the fermenter to a final level not to exceed 0.5%. Cells are
removed by centrifugation and the resulting supernatant is filtered with a
30 depth filter having pore sizes in the range of 0.25 – 2.0 µm. The
temperature is maintained at 5 °C ± 3 °C during this process. The
inactivated culture supernatant is then diafiltered and concentrated 10-30
fold using ultrafiltration with filters not greater than 20,000 molecular
weight cutoff. Concentrated supernatant is stored at 2-8 °C for future
35 blending into vaccines. Prior to blending, the concentrated supernatant is
assayed for potency by using the combining power test (TCP) described
above. The potency of each batch of toxoid is assigned in TCP units per
mL.

- 5 Vaccine: The supernatant comprising the inactivated *C. perfringens* type A *alpha* toxoid is blended as a water-in-oil emulsion containing 4 Combining Power Units (TCP) per mL. The emulsion is prepared with 70% oil phase and 30% aqueous phase.

The oil phase is prepared as follows:

10	Mineral oil	89.20%
	Span 80	10.00%
	Benzyl alcohol	0.75%
	Triethanolamine	0.05%

- 15 The aqueous phase is prepared as follows:

<i>C. perfringens</i> type A toxoid + saline	88%
33% Tween 80/saline solution	12%

- 20 A total of 30% aqueous phase is added slowly to the 70% oil phase and emulsified with a Silverson homogenizer. (Other inline homogenizers may also be used). The time of homogenization depends on the volume of the emulsion and is determined by viscosity, particle size, and stability of the emulsion for at least three days at 37 °C. Gentamicin is added to the aqueous phase to provide a final concentration of up to 30 µg/mL of serial volume. Thimerosol is added to the aqueous phase to provide a final concentration of up to 0.01% of serial volume.

- 30 Vaccination: The pullets are vaccinated subcutaneously with 0.5 mL per dose of the blended vaccine. The first dose of vaccine is administered at 14 weeks of age, and the second dose is administered at 20 weeks of age. Twenty broiler pullets are vaccinated with the blended vaccine described above containing 1 TCP per dose. A second group of twenty pullets are vaccinated with the blended vaccine described above containing 2 TCP per dose. A third group of twenty pullets are used as controls and are not vaccinated. A total of 2-3 roosters are commingled with each group of pullets to produce fertilized eggs.

5 Passive Immunity

Eggs are collected from 32, 52, and 65 week-old vaccinated and control hens. The progeny chicks hatched from these eggs are used to evaluate passive protection as listed in Table 1.

10

TABLE 1
NUMBER OF PROGENY CHICKS USED AT EACH TIME POINT

<u>Hens age</u>	<u>Progeny chicks in vaccinate group</u>	<u>Progeny chicks in challenge control group</u>
32 Weeks	9	9
52 Weeks	30	20
65 Weeks	14	18

15 The chicks are fed a non-medicated high protein diet for the first two weeks and then switched to normal feed for the remainder of the trial. Each bird is orally challenged with a virulent *C. perfringens* Type A that expresses both the *alpha* toxin and the *beta* 2 toxin. The challenge dose contains 6.3×10^7 to 6.3×10^8 colony forming units per mL, in a 3 mL dose. The birds are challenged for 3 consecutive days starting at 18 or 19 days of age. Two days after the last day of the challenge the birds are sacrificed and then examined for necrotic enteritis lesions. The efficacy results for the progeny chicks are listed individually in Tables 2-4, denoting the vaccination status of the individual chick's mother, and the extent of its necrotic enteritis lesions, if any, according to the Rating Scale provided below. Table 2 denotes progeny chicks from 32 week-old hens, Table 3 denotes progeny chicks from 52 week-old hens, and Table 4 denotes progeny chicks from 65 week-old hens. Table 5 shows the median score for progeny chicks from hens that were vaccinated with 2 TCP per dose. As shown, the progeny of the vaccinated hens are significantly protected against the administered bacterial challenge relative to the progeny of unvaccinated hens.

5 Rating Scale for Necrotic Enteritis (NE) Lesions

- 0 = No necrotic enteritis gross lesions in the small intestine; intestine has normal elasticity (rolls back on itself after being opened).
- 10 1 = Thin and flaccid intestinal wall (intestine remains flat when opened and doesn't roll back into normal position); excess or thickened mucus covering mucus membrane or focal or multifocal mild reddening of the mucosa or congestion of the serosal vessels.
- 15 2 = Single or few multifocal areas of reddening and swelling of the intestinal wall; single or few multifocal areas of ulceration or necrosis of the intestinal mucosa.
- 20 3 = Extensive multifocal areas of necrosis and ulceration of the intestinal mucosa $\pm$ significant hemorrhage or layer of fibrin or necrotic debris on the mucosal surface (Turkish towel appearance).
- 25 4 = Dead animal with necrotic enteritis gross lesions scored 2 or above.

TABLE 2
NECROTIC ENTERITIS LESION SCORES IN
INDIVIDUAL PROGENY CHICKS FROM 32 WEEK-OLD HENS

30

<u>Non-vaccinated</u> <u>non-challenged</u> <u>controls</u>	<u>Non-vaccinated</u> <u>challenge</u> <u>controls</u>	<u>Vaccine</u> <u>with 1 TCP</u> <u>per dose</u>	<u>Vaccine</u> <u>with 2 TCP</u> <u>per dose</u>
0	1	4	1
0	2	1	0
0	1	2	0
0	1	1	1
	2	1	0
	3	3	1
	3	0	1
	1	4	1
	4	1	4
		3	
		1	
		1	
		1	
Mean= 0	2.0	1.8	1.0
Median = 0	2.0	1.0	1.0

5

TABLE 3
NECROTIC ENTERITIS LESION SCORES IN
INDIVIDUAL PROGENY CHICKS FROM 52 WEEK-OLD HENS

<u>Non-vaccinated non-</u> <u>challenged controls</u>	<u>Non-vaccinated</u> <u>challenge controls</u>	<u>Vaccine with 2</u> <u>TCP per dose</u>
0	4	0
0	3	1
0	3	1
0	1	1
0	1	0
	2	1
	1	2
	1	1
	1	1
	2	0
	2	0
	2	0
	1	0
	1	1
	2	2
	2	0
	1	1
	2	0
	1	0
	1	0
		0
		0
		2
		1
		0
		1
		0
		1
		0
		2
		0
Mean=	0	1.7
Median =	0	1.5
		0.6
		0.5

TABLE 4
NECROTIC ENTERITIS LESION SCORES IN
INDIVIDUAL PROGENY CHICKS FROM 65 WEEK-OLD HENS

<u>Non-vaccinated non-</u> <u>challenged controls</u>	<u>Non-vaccinated</u> <u>challenge controls</u>	<u>Vaccine with 2</u> <u>TCP per dose</u>
0	4	0
0	0	0
0	0	0
0	2	2
	0	2
	0	0
	3	0
	3	3
	2	0
	0	2
	3	0
	2	0
	0	0
	0	0
	0	0
	2	
	3	
	3	
Mean= 0	1.5	0.6
Median = 0	2.0	0.0

TABLE 5
MEDIAN SCORE IN PROGENY CHICKS FROM
HENS VACCINATED WITH A DOSE OF 2 TCP

<u>TREATMENT</u> <u>GROUPS</u>	<u>MEDIAN NECROTIC ENTERITIS LESION SCORE</u> <u>FROM PROGENY OF HENS</u>		
	<u>32 WEEKS OLD</u>	<u>52 WEEKS OLD</u>	<u>65 WEEKS OLD</u>
Vaccinate group	1	0.5	0
Control group	2	1.5	2

Antibody Titers

Sera: Blood samples are collected from hens at 33 and 78 weeks of age. Blood is allowed to clot for 2-4 hours at room temperature and then sera is obtained following centrifugation. Sera is stored at -10 °C or colder until tested for antibody titer. The antibody titer to *C. perfringens alpha* toxin is evaluated by a haemolysis inhibition assay using serial dilutions and sheep red blood cells as follows: Serial dilutions (two-fold) are made in a V-bottom microtiter plate for each sample tested. A known amount of *alpha* toxin is added to each well containing a dilution of the sample. The plates are then incubated for one hour at 36 ± 2 °C to allow the antibodies obtained from the sera to complex with the *alpha* toxin. Following this incubation, a 0.5% solution of sheep red blood cells are added to the wells and the plates are incubated for three hours at 36 ± 2 °C to allow uncomplexed *alpha* toxin to lyse the red blood cells. The plates are then checked for the absence of haemolysis. The reciprocal of the highest dilution of the test sample that shows no haemolysis is considered the end point. The antibody titers are shown in Tables 6-8.

Egg Yolks: Egg yolks are processed to determine the antibody titer. Briefly, the yolk is separated and mixed with commercial extraction buffer (Promega EGGstract System®, Promega Catalog No. G1531 and G2610, Madison, Wisconsin). Following the extraction, an IgY pellet is obtained, which is then resuspended to the original volume of yolk with phosphate buffered saline. Egg yolk extract is pooled from at least 5 eggs and tested for antibody titer using a haemolysis inhibition (HI) assay as described for the sera above. The yolks from eggs collected from layers at 40, 52, and 65 weeks of age are evaluated for antibody titer in this manner. The antibody titers for the egg yolks are shown in Table 9.

TABLE 6
INDIVIDUAL HEN SERUM ANTIBODY TITER TO
C. PERFRINGENS TYPE A ALPHA TOXIN AT 33 WEEKS OF AGE

<u>Vaccinated hens</u> <u>(2 TCP/Dose)</u>	<u>Control hens*</u>
1024	1
8192	2
256	1
1024	2
1024	2
256	2
256	2
1024	2
512	1
64	1
Geomean = 588	Geomean ≤ 2

*Values < 2 were considered as 1 for the purpose of calculating the geometric mean

TABLE 7
INDIVIDUAL HEN SERUM ANTIBODY TITER TO
C. PERFRINGENS TYPE A ALPHA TOXIN AT 78 WEEKS OF AGE

<u>Vaccinated hens</u> <u>(2 TCP/Dose)</u>	<u>Control hens*</u>
512	2
32	2
128	2
512	2
128	1
16	1
1024	1
512	2
8192	2
128	4
64	2
512	8
64	16
1024	
256	
128	

Geomean = 235 Geomean = 2

*Values < 2 were considered as 1 for the purpose of calculating the geometric mean

TABLE 8
GEOMETRIC MEAN HAEMOLYSIS INHIBITION TITER IN SERA
OF HENS AT VARIOUS TIME POINTS

<u>TREATMENT GROUPS</u>	<u>TITER IN SERUM</u> <u>(AGE AT SAMPLE COLLECTION)</u>	
	<u>33 WEEKS</u>	<u>78 WEEKS</u>
<u>VACCINATE GROUP</u> <u>(2 TCP/DOSE)</u>	588	235
<u>CONTROL GROUP</u>	≤2	2

TABLE 9
HAEMOLYSIS INHIBITION TITER IN EGG YOLK
FROM HENS COLLECTED AT VARIOUS TIME POINTS

<u>TREATMENT GROUPS</u>	<u>TITER IN EGG YOLK</u> <u>(AGE AT EGG COLLECTION)</u>		
	<u>40 WEEKS</u>	<u>52 WEEKS</u>	<u>65 WEEKS</u>
<u>VACCINATE GROUP</u>	515	2048	64
<u>CONTROL GROUP</u>	≤2	2	≤2

EXAMPLE 2
EFFICACY OF VACCINE IN BROILER HENS
VACCINATED BY AN INTRAMUSCULAR ROUTE

Summary

Vaccination of broiler hens by an intramuscular route using a vaccine comprising a single *C. perfringens* Type *alpha* toxoid (Type A), also results in (i) an immunogenic response in the vaccinated broiler hens, (ii) significant

anti-*alpha* toxoid antibody in the eggs of the vaccinated broiler hens, and (iii) passive protection for the subsequently born offspring of the vaccinated broiler hens.

Passive Immunity

A total of 14 broiler pullets are intramuscularly vaccinated with two doses of a 0.5 mL of the vaccine of Example 1 above, containing 2 TCP. An additional group of 40 pullets are used as controls. Three roosters are commingled with each group of pullets, as described above. The first dose of vaccine is administered at 10 weeks of age and the second dose is administered at 23 weeks of age. The eggs are collected from the hens at 32 weeks of age and hatched to determine passive protection in the progeny chicks following an experimental *C. perfringens* challenge.

Table 10 shows the incidence of necrotic enteritis and the median score for its corresponding lesions as determined by the Rating Scale of Example 1 above, for the progeny chicks of vaccinated and control hens. Table 11 shows that median score for the necrotic enteritis lesions for the individual progeny chicks. Table 12 lists the antibody titers against *C. perfringens* Type A *alpha* toxin of the individual progeny chicks, whereas, the antibody titers for the egg yolks from eggs collected from the vaccinated and control hens at 32 weeks of age are provided in Table 13.

TABLE 10
INCIDENCE OF DISEASE AND NECROTIC ENTERITIS LESION

<u>TREATMENT</u> <u>GROUPS</u>	<u>Number</u> <u>of birds</u>	<u>%</u> <u>Incidence</u>	<u>Median</u> <u>Score</u>	<u>Mean</u> <u>Score</u>
<u>VACCINATE</u> <u>GROUP</u>	8	0 (0/8)	0	0
<u>CONTROL</u> <u>GROUP</u>	29	76 (22/29)	2	1.7

TABLE 11
NECROTIC ENTERITIS LESION SCORES IN INDIVIDUAL
PROGENY CHICKS FROM 32 WEEK-OLD HENS

<u>Non-vaccinated</u> <u>non-challenged</u> <u>controls</u>	<u>Non-vaccinated</u> <u>challenge controls</u>	<u>Vaccine with 2</u> <u>TCP per dose</u>
0	1	0
0	2	0
0	1	0
0	0	0
0	0	0
0	1	0
	3	0
	0	0
	1	
	0	
	2	
	2	
	1	
	3	
	3	
	3	
	2	
	2	
	3	
	1	
	3	
	0	
	2	
	0	
	0	
	3	
	2	
	4	
	4	
Mean =	0.0	1.7
Median =	0.0	2.0
		0.0

TABLE 12
SERUM ANTIBODY TITER OF
INDIVIDUAL HENS AT 35 WEEKS OF AGE²

<u>VACCINATED HENS</u> (2 TCP/Dose)	<u>CONTROL HENS³</u>
128	1
512	1
65536	1
4096	1
1024	1
512	1
2048	1
1024	1
512	2
256	1
1024	1
128	1
256	1
256	1
1024	1
1024	2
64	32
681	2
	2
	1
	2
	1
	1
	2
	2
	2
	2
	1
	2
	32
	1
	2
	1
	1
	2
	1
	1
	1

² Antibodies to *C. perfringens* Type A *Alpha* Toxin as Measured by Haemolysis Inhibition Assay described in Example 1 above.

³ Values < 2 were considered as 1 for the purpose of calculating the geometric mean.

Geomean = 681 ≤ 2

TABLE 13
ANTIBODY TITER IN EGG YOLK COLLECTED
FROM HENS AT 32 WEEKS OF AGE

<u>TREATMENT GROUPS</u>	<u>HAEMOLYSIS</u> <u>INHIBITION TITER</u>
<u>VACCINATE GROUP</u>	512
<u>CONTROLS GROUP</u>	<2

EXAMPLE 3
SEROLOGY IN SPF WHITE LEGHORN PULLETS
VACCINATED BY A SUBCUTANEOUS ROUTE

Antibody Titers

Antibody titers are evaluated in SPF white leghorn pullets that are vaccinated subcutaneously with the vaccine of Example 1 above, containing 1, 2, or 3 TCP. The pullets are vaccinated at 15 weeks of age with 0.5 mL of the vaccine and a booster dose is administered 4 weeks following the initial vaccination. Blood samples are collected 6 weeks following the booster vaccination. Serum from each individual bird is evaluated for antibody titer by the haemolysis inhibition assay as described above in Example 1.

TABLE 14
INDIVIDUAL PULLET SERUM ANTIBODY TITER TO
***C. PERFRINGENS* TYPE A ALPHA TOXIN**

<u>1 TCP/DOSE</u>		<u>2 TCP/DOSE</u>		<u>3 TCP/DOSE</u>		<u>CONTROLS</u>	
<u>Bird Id</u>	<u>Titer</u>	<u>Bird Id</u>	<u>Titer</u>	<u>Bird Id</u>	<u>Titer</u>	<u>Bird Id</u>	<u>Titer*</u>
923	4096	932	1024	922	1024	921	4
924	1024	938	8192	927	64	928	<2
925	4	940	512	931	2048	929	2
926	2048	942	1024	935	4096	933	2
930	512	943	2048	945	1024	937	2
941	1024	948	2048	947	2048	946	2
953	32	949	2048	952	1024	957	2
954	2	950	2048	956	128	966	<2
955	32	951	512	959	512		
962	512	958	512	960	64		
965	4096	961	512	963	2048		
967	512	964	2048	968	2048		
Geomean	242		1290		724		≤2

* Titers of <2 are considered as 1 for determining geometric mean titer

The antibody titer in the eggs collected at 25 week of age from the white leghorn layers are evaluated for haemolysis inhibition titer. The results are tabulated in Table 15.

TABLE 15
POOLED EGG YOLK ANTIBODY TITER TO
***C. PERFRINGENS* TYPE A ALPHA TOXIN**

<u>GROUP</u>	<u>VACCINE</u>	<u>ANTIBODY TITER</u>
1	1 TCP	512
2	2 TCP	512
3	3 TCP	512
4	Controls	<2

DETERMINATION OF TOXIN NEUTRALIZATION TITER (TNT)
IN POOLED SERA OF WHITE LEGHORN HENS

Antitoxin titer to *C. perfringens* Type A alpha toxin in the pooled serum of the hens is evaluated using mice. The pooled sera are tested for anti-

toxin titer using a method as described in Code of Federal Regulations, Animal and Plant Health Inspection Service, Department of Agriculture. The methods used to measure the antitoxin was similar to the current 9 CFR §113.111 (c), except that *alpha* toxin and antitoxin reagents are used instead of *beta* toxin and antitoxin. The following test reagents are used to determine the antitoxin titer:

- 1) *C. perfringens* Type A *alpha* antitoxin: IRP 426 (obtained from Center for Veterinary Biologics, USDA).
- 2) *C. perfringens* Type A *alpha* toxin IRP 446 (obtained from Center for Veterinary Biologics, USDA).

Briefly, diluted standard antitoxin or sera are combined with a known amount of standard *alpha* toxin. The presence of un-neutralized toxin is then detected by injection of the mixture into mice. Comparison to the effects of known amounts of standard *alpha* antitoxin on toxin activity are then evaluated by determining the dilution of standard or test sera that protects the mice from death in a bioassay. The antitoxin titer in the pooled sera of white leghorn pullets are as shown in Table 16 below.

TABLE 16
TOXIN NEUTRALIZATION TITER (TNT) IN
VACCINATED AND CONTROL PULLETS

<u>GROUP</u>	<u>VACCINE</u>	<u>ANTITOXIN TITER IN SERUM</u>	
		<u>Pre-vaccination</u>	<u>Post -vaccination</u>
1	1 TCP	<1	≥2 and <4
2	2 TCP	<1	≥4
3	3 TCP	<1	≥4
4	Controls	<1	<1

EXAMPLE 4

SEROLOGY IN SPF WHITE LEGHORN PULLETS VACCINATED BY AN INTRAMUSCULAR ROUTE

Antibody Titers

Antibody titers in SPF white leghorn pullets that are vaccinated twice intramuscularly with vaccine of Example 1 above, containing 1, 2, or 3 TCP

are evaluated. The pullets are vaccinated at ten weeks of age with 0.5 mL of the vaccine and a booster dose is given four weeks following initial vaccination. Blood samples are collected seven weeks following booster vaccination. The individual pullet sera is evaluated for antibody titer by haemolysis inhibition assay as described in Example 1 above, and is tabulated in Tables 17 and 18 below.

TABLE 17
INDIVIDUAL PULLET SERUM ANTIBODY TITER TO
***C. PERFRINGENS* TYPE A ALPHA TOXIN**

1 TCP		2 TCP		3 TCP		Controls	
Bird Id	Titer	Bird Id	Titer	Bird Id	Titer	Bird Id	*Titer
951	256	631	1024	646	4096	661	<2
952	128	632	2048	647	4096	662	<2
953	1024	633	2048	648	2048	663	8
954	128	634	256	649	2048	664	<2
955	2048	635	128	650	4096	665	8
956	512	636	2048	651	2048	666	4
957	1024	637	512	652	2048	667	<2
958	256	638	2048	653	1024	668	<2
960	512	639	1024	654	4096	669	<2
961	2048	640	2048	655	4096	670	<2
962	1024	641	2048	656	4096	671	<2
964	1024	642	1024	657	4096	672	<2
965	256	643	1024	658	1024	673	16
		644	512	660	1024	674	16
		645	2048	966	4096	675	16
Geomean	540		1024		2580		3

* Titers of <2 are considered as 1 for determining geometric mean titer

Toxin neutralization titer (TNT) in pooled sera of hens is evaluated using the procedure as described in Example 3 above, and the results are provided in Table 18 below.

TABLE 18
TOXIN NEUTRALIZATION TITER (TNT) IN
VACCINATED AND CONTROL PULLETS

<u>GROUP</u>	<u>VACCINE</u>	<u>ANTITOXIN TITER IN SERUM</u>	
		<u>Pre-vaccination</u>	<u>Post-vaccination</u>
1	1 TCP	<1	≥4
2	2 TCP	<1	≥4
3	3 TCP	<1	≥4
4	Controls	<1	<1

The antibody titer in the eggs collected at 25 week of age from these white leghorn layers are evaluated for haemolysis inhibition titer as described in Example 1 above. The results are summarized below in Table 19.

TABLE 19
POOLED EGG YOLK ANTIBODY TITER TO
***C. PERFRINGENS* TYPE A ALPHA TOXIN**

<u>GROUP</u>	<u>VACCINE</u>	<u>ANTIBODY TITER</u>
1	1 TCP	512
2	2 TCP	256
3	3 TCP	512
4	Controls	<2

EXAMPLE 5
COMPARISON OF A MUTIVALENT AND A MONOVALENT
***C. PERFRINGENS* ALPHA TOXOID VACCINE IN PORCINE**

Summary

Methods are described for providing passive protection in neonatal pigs by vaccinating the pregnant sows/gilts with the *C. perfringens* type A alpha toxoid vaccines of the present invention. The results show an antibody response in sows that can be transferred to piglets through colostrum.

Materials

C. perfringens Type A alpha toxoid: *C. perfringens* Type A alpha toxoid was prepared as described in Example 1 above.

Vaccine: A vaccine of the present invention can be blended with inactivated *C. perfringens* type A *alpha* toxoid containing >2 Total Combining Power Units. The vaccine can be blended with any adjuvant disclosed herein, including oil-in-water emulsion containing mineral oils, vegetable oils (peanut oil, soybean oil), squalene, squalane and other metabolizable oils. Other adjuvants such as Seponin, CARBOPOL®, and aluminum containing adjuvants (aluminum hydroxide, aluminum phosphate) also can be used in vaccine preparation. The vaccine *can* further contain other antigens including *E. coli* (K88, K99, 987P, Type 1), toxoids from *C. perfringens*, and/or toxoids from other pathogenic bacteria including *Clostridium difficile*, rotavirus, and/or Cryptosporidia.

Administration

The vaccines are administered to pregnant gilts/sows prior to farrowing by either intramuscular or subcutaneous route in order to provide passive protection in neonatal pigs through the ingestion of colostrum.

Results

The study is conducted in 32 week-old pigs comparing three vaccines:

Vaccine #1: blended with an aluminum hydroxide adjuvant containing 4 TCP of *C. perfringens* Type A *alpha* toxoid in a 2 mL dose.

Vaccine #2: blended with 4 TCP of *C. perfringens* type A *alpha* toxoid, *E. coli* K88, *E. coli* K99, *E. coli* 987P, *E. coli* Type 1 and *C. perfringens* type C *beta* toxoid in a 2 mL dose.

Vaccine #3: prepared as a placebo vaccine containing no *C. perfringens* type A *alpha* toxoid, but containing *E. coli* K88, *E. coli* K99, *E. coli* 987P, *E. coli* Type 1 and *C. perfringens* type C *beta* toxoid in a 2 mL dose.

One group of ten pigs is vaccinated intramuscularly with 2 mL of Vaccine #1. A second group of ten pigs is vaccinated intramuscularly with 2 mL of Vaccine #2. The third group of seven pigs is vaccinated with 2 mL of Vaccine #3. A booster dose of 2mL is given 20 days following the initial

vaccinations. The sera samples are collected at the time of initial vaccination (Day 0), 20 days after the booster vaccination (Day 40) and 41 days after booster vaccination (Day 61). The sera samples are then evaluated for antibody titer to *alpha* toxin by the haemolysis inhibition assay described in Example 1 above. The results for the three vaccines are individually shown in Tables 20-22, respectively.

TABLE 20**MONOVALENT *C. PERFRINGENS* TYPE A ALPHA TOXOID VACCINE**

Pig #	Haemolysis Inhibition Titer		
	Day 0 (Pre-vac)	Day 40	Day 61
10268	32	256	256
10277	2	8	8
10278	16	32	32
10295	16	64	128
10307	16	64	128
10312	8	64	64
10316	2	16	16
10317	---	64	64
10324	64	128	256
10331	16	32	32
Geomean	12	49	60

TABLE 21

C. PERFRINGENS TYPE A ALPHA TOXOID COMBO VACCINE
WITH *E. COLI*- *C. PERFRINGENS* TYPE C BETA TOXOID

Haemolysis Inhibition Titer			
Pig #	Day 0 (Pre- vac)	Day 40	Day 61
10264	16	64	64
10266	32	128	128
10269	2	32	32
10276	2	256	256
10280	8	32	32
10282	4	32	32
10287	16	64	64
10290	16	256	256
10321	16	128	64
10330	4	64	64
Geomean	8	79	74

TABLE 22

E. COLI – *C. PERFRINGENS* TYPE C BETA TOXOID

Haemolysis Inhibition Titer			
Pig #	Day 0 (Pre- vac)	Day 40	Day 61
Group 3	Day 0	Day 40	Day 61
10272	4	32	32
10292	16	32	32
10303	2	16	16
10305	2	32	32
10313	8	8	8
10318	4	16	16
10319	4	64	64
Geomean	4	24	24

EXAMPLE 6

**DETERMINATION OF TOXIN NEUTRALIZATION TITER (TNT)
IN POOLED SERA OF VACCINATED SOWS**

Four pregnant sows are evenly divided into two treatment groups. One group is vaccinated by intramuscular route with 2.0 mL of vaccine containing 4 TCP in a 2 mL dose of Vaccine #1 of Example 5 above. The other group is the controls who are not vaccinated. The sows are vaccinated at approximately 6-7 weeks prior to farrowing, and a booster

dose is given three weeks later. Blood samples are collected before vaccination, and just prior to farrowing. Table 23 shows the evaluation of the sera samples for antitoxin titer to *alpha* toxin using a toxin neutralization test (TNT) as described in Example 3 above.

TABLE 23

TNT TITER

<u>Treatment Group</u>	<u>Sow Number</u>	<u>Pre-vaccination (TNT)</u>	<u>Post-Booster vaccination (TNT)</u>
Vaccinate	10614	<1	>4 <8
Vaccinate	10616	<1	>4 <8
Control	10615	<2	<2
Control	10617	<1	<2

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications are cited herein, the disclosures of which are hereby incorporated by reference in their entireties.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

The claims defining the invention are as follows:

1. A vaccine against *C. perfringens* comprising a *C. perfringens* *alpha* toxoid supernatant that was concentrated by ultrafiltration and has 2 or more Total
5 Combining Power (TCP);
wherein the *C. perfringens* *alpha* toxoid supernatant comprises an *alpha* toxoid antigen; with the proviso that only a single *C. perfringens* Type *alpha* toxoid antigen is present in said vaccine.
- 10 2. The vaccine of Claim 1, wherein the antigen is in a cell-free preparation.
3. The vaccine of Claim 1, wherein the vaccine is for administration to a chicken.
4. The vaccine of Claim 1, wherein the antigen is a recombinant polypeptide.
- 15 5. The vaccine of Claim 3 wherein one to two doses of 0.25 - 0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of a chicken vaccinated with the vaccine.
- 20 6. The vaccine of Claim 1, wherein said antigen is selected from the group consisting of a *C. perfringens* Type A *alpha* toxoid and a *C. perfringens* Type C *alpha* toxoid.
7. The vaccine of Claim 1, further comprising an adjuvant.
- 25 8. The vaccine of Claim 1, wherein a water-in-oil emulsion comprises the antigen.
9. The vaccine of Claim 8, wherein the water-in-oil emulsion was prepared with
30 a 70% oil phase and a 30% aqueous phase.
10. The vaccine of Claim 6, wherein the antigen is a *C. perfringens* Type A *alpha* toxoid.

11. The vaccine of Claim 1, which is a multivalent vaccine further comprising one or more of the following toxins: *C. perfringens* beta toxin, *C. perfringens* beta 2 toxin, *C. perfringens* enterotoxin, *C. perfringens* epsilon toxin, *C. perfringens* iota toxin, *C. perfringens* kappa toxin, *C. perfringens* lambda toxin, *C. perfringens* theta toxin, *C. sordellii* hemorrhagic toxin, *C. sordellii* lethal toxin, *C. difficile* A toxin, *C. difficile* B toxin, *C. septicum* alpha toxin, *C. novyi* alpha toxin, and *C. novyi* beta toxin.

12. The vaccine of Claim 11, wherein the multivalent vaccine further comprises one or more viral antigens, one or more bacterial antigens, and one or more parasitic antigens;

wherein the one or more viral antigens is from one or more of the following sources: infectious bursal disease virus, infectious bronchitis virus, reovirus, and Newcastle disease virus;

wherein the one or more bacterial antigens is from one or more of the following sources: *E. coli*, *Salmonella*, and *Campylobacter*; and

wherein the one or more parasite antigens is from *Eimeria*.

13. The vaccine of Claim 1, which is a multivalent vaccine that further comprises one or more additional antigens;

wherein the additional antigen is from one or more of the following sources: infectious bursal disease virus, infectious bronchitis virus, reovirus, Newcastle disease virus, *E. coli*, *Salmonella*, *Campylobacter*, and *Eimeria*.

14. A vaccine consisting essentially of an antigen selected from the group consisting of a single *C. perfringens* Type alpha toxoid, an antigenic fragment of the alpha toxoid, an inactive antigenic fragment of a single *C. perfringens* Type alpha toxin, and any combination thereof;

wherein the single *C. perfringens* Type alpha toxoid and the inactive antigenic fragment of the single *C. perfringens* Type alpha toxin are the same Type; and

wherein one to two doses of 0.25 - 0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of a chicken vaccinated with the vaccine.

- 5 15. A method of providing passive immunity against multiple poultry diseases to the progeny of a female avian comprising administering the vaccine of Claim 12 to the female avian prior to her laying of the eggs that comprise the progeny; wherein the progeny are provided passive immunity from multiple diseases.
- 10 16. A method of providing passive immunity against a clostridial disease to the progeny of a female avian, said method comprising administering the vaccine of Claim 1 to the female avian prior to her laying of the eggs that comprise the progeny; wherein the progeny are provided passive immunity.
- 15 17. The method of Claim 16 wherein the avian is a chicken or a turkey.
18. The method of Claim 16 wherein the clostridial disease is a clostridial enteric disease.
- 20 19. The method of Claim 18 wherein the clostridial enteric disease is necrotic enteritis.
20. The method of Claim 16 wherein the clostridial disease is selected from the group consisting of cholangiohepatitis, gangrenous dermatitis, and cellulitis.
- 25 21. A method of making a *C. perfringens alpha* toxoid vaccine comprising:
- (a) growing a *C. perfringens* cell in a culture medium to produce a quantity of cultured cells; wherein said quantity of cultured cells secrete a *C. perfringens alpha* toxin into the cell medium;
- 30 (b) inactivating the secreted *alpha* toxin to produce a *C. perfringens alpha* toxoid;

(c) removing a majority of the quantity of cultured cells from the culture medium to form a *C. perfringens alpha* toxoid supernatant; and

(d) adjusting the concentration of the *C. perfringens alpha* toxoid supernatant so that it is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of an avian that has been vaccinated with either one or two doses of 0.25 - 0.6 mL per dose of said vaccine.

22. The method of Claim 21, further comprising mixing the *C. perfringens alpha* toxoid supernatant with a water-in-oil emulsion.

23. The method of Claim 22, wherein the water-in-oil emulsion is prepared with 70% oil phase and 30% aqueous phase.

24. The method of Claim 23 wherein the *C. perfringens* cell is a single *C. perfringens* Type cell.

25. The method of Claim 24 wherein said single *C. perfringens* Type cell is selected from the group consisting of a *C. perfringens* Type A cell and a *C. perfringens* Type C cell.

26. A vaccine against *C. perfringens* for a chicken comprising a *C. perfringens* Type A *alpha* toxoid supernatant that was concentrated by ultrafiltration and has 2 or more Total Combining Power (TCP);

wherein the *C. perfringens* Type A *alpha* toxoid supernatant comprises an *alpha* toxoid antigen;

wherein a water-in-oil emulsion comprises the antigen; and

wherein one to two doses of 0.25 - 0.6 mL per dose of the vaccine is sufficient to induce at least four antitoxin units (A.U.) of anti-*alpha* toxin antibody per mL of antisera of a chicken vaccinated with the vaccine; with the proviso that only a single *C. perfringens* Type *alpha* toxoid antigen is present in said vaccine.

27. The vaccine of Claim 26 wherein the water-in-oil emulsion was prepared with a 70% oil phase and a 30% aqueous phase.

5 28. Use of the vaccine of Claim 12 in the manufacture of a medicament for providing passive immunity against multiple poultry diseases to the progeny of a female avian.

10 29. Use of the vaccine of Claim 1 in the manufacture of a medicament for providing passive immunity against a clostridial disease to the progeny of a female avian.